



HAL
open science

A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein

Véronique Pons, Corinne Rolland, Michel Nauze, Marie Danjoux, Gérald Gaibelet, Anne H. Durandy, Agnes Sassolas, Emile Lévy, François Tercé, Xavier Collet, et al.

► **To cite this version:**

Véronique Pons, Corinne Rolland, Michel Nauze, Marie Danjoux, Gérald Gaibelet, et al.. A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein. *Human Mutation*, 2011, 32 (7), pp.751. 10.1002/humu.21494 . hal-00651635

HAL Id: hal-00651635

<https://hal.science/hal-00651635v1>

Submitted on 14 Dec 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0522.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	07-Feb-2011
Complete List of Authors:	<p>Pons, Véronique; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Rolland, Corinne; INSERM, U1043; Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP) Nauze, Michel; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Danjoux, Marie; CHU Toulouse, Hôpital Purpan, Département d'Anatomopathologie Gaibelet, Gérald; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Durandy, Anne; INSERM U768, Université Paris V-René Descartes, Hôpital Necker-Enfants Malades Sassolas, Agnes; UF Dyslipidémies, CBPE, Hospices Civils de Lyon and Lyon University, INSERM U1060, CarMeN Laboratory, Univ Lyon-1 Lévy, Emile; Départements de Nutrition et de Biochimie, Hôpital Sainte-Justine et Université de Montréal Tercé, François; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Collet, Xavier; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires MAS, Emmanuel; INSERM, U1043; Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP); CHU Toulouse, Hôpital des Enfants, Unité de Gastroentérologie, Hépatologie et Nutrition, Département de Pédiatrie</p>
Key Words:	abetalipoproteinemia, MTTP, triglyceride transfer, endoplasmic reticulum, intestinal HDL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

New splicing mutations of *MTTP*

1

Formatted: Font: Italic

A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein

Véronique Pons^{1,2}, Corinne Rolland^{3,4}, Michel Nauze^{1,2}, Marie Danjoux⁵, Gérald Gaibelet^{1,2}, Anne Durandy⁶, Agnès Sassolas⁷, Emile Lévy⁸, François Tercé^{1,2}, Xavier Collet^{1,2*} and Emmanuel Mas^{3,4,9*}

¹INSERM, U1048, Toulouse, F-31000, France;

²Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, F-31300, France;

³INSERM, U1043, Toulouse, F-31300 France;

⁴Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France;

⁵CHU Toulouse, Hôpital Purpan, Département d'Anatomopathologie, Toulouse, F-31300 France;

⁶INSERM, U768, Université Paris V-René Descartes, Hôpital Necker-Enfants Malades, 75015 Paris (France);

⁷UF Dyslipidémies, CBPE, Hospices Civils de Lyon and Lyon University, INSERM, U1060, CarMeN Laboratory, Univ Lyon-1 F-69621, Villeurbanne, (France);

⁸Départements de Nutrition et de Biochimie, Hôpital Sainte-Justine et Université de Montréal, Montréal, Québec (Canada);

⁹CHU Toulouse, Hôpital des Enfants, Unité de Gastroentérologie, Hépatologie et Nutrition, Département de Pédiatrie, Toulouse, F-31300, France.

* These authors equally contributed to the work

Corresponding author:

Emmanuel Mas, MD

Hôpital des Enfants - Unité de Gastroentérologie, Hépatologie et Nutrition – 330 avenue de Grande-Bretagne – TSA 70034 – 31059 Toulouse cedex 9 (France)

Tel. (33) 5 34 55 84 45

Fax. (33) 5 34 55 85 67

E-mail: mas.e@chu-toulouse.fr

Deleted: 1.

Deleted: 2...3 ... [1]

Deleted: 4

Deleted: 4

Deleted: 5

Deleted: 5

Deleted: 6

Deleted: 7...1. ... [2]

Deleted: 2...7 ... [3]

Deleted: 8

Deleted: 8

Formatted: Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France

Deleted: U563... ... [4]

Deleted: 3

Formatted ... [5]

Deleted:

Formatted ... [6]

Deleted: France

Formatted ... [7]

Deleted: 3

Formatted: Superscript

Deleted: III Paul-Sabatier,

Deleted: 4

Deleted: 3

Deleted: Hôpital Purpan,

Deleted: 4

Deleted: 5... ... [8]

Deleted: Université Paris Descartes, Faculté de Médecine Paris V-René Descartes,

Deleted: 5

Deleted: 6

Formatted ... [9]

Deleted: Laboratoire des Dyslipidémies, Centre de Biologie Est, Lyon

Deleted: 6

Deleted: 7

Deleted: 7

Deleted: 8... Hôpital des Enfants ... [10]

Deleted: 9

New splicing mutations of *MTTP*

2

Formatted: Font: Italic

ABSTRACT

Abetalipoproteinemia is a rare autosomal recessive disease characterized by low lipid levels and by the absence of apoB-containing lipoproteins. It is the consequence of microsomal triglyceride transfer protein (*MTTP*) deficiency.

We report 2 patients with new *MTTP* mutations. We studied their functional consequences on the triglyceride transfer function using duodenal biopsies. We transfected *MTTP* mutants in HepG2 and HeLa cells to investigate their association with protein disulfide isomerase (*PDI*) and their localization at the endoplasmic reticulum.

Deleted: ed

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTP*

Formatted: Font: Italic

Formatted: Font: Italic

These children have a severe abetalipoproteinemia. Both of them had also a mild hypogammaglobulinemia. They are compound heterozygotes with c.619G>T and c.1237-28A>G mutations within *MTTP* gene. mRNA analysis revealed abnormal splicing with deletion of exon 6 and 10, respectively. Deletion of exon 6 ($\Delta 6$ -*MTTP*) introduced a frame shift in the reading frame and a premature stop codon at position 234. Despite $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* mutants were not capable of binding *PDI*, both *MTTP* mutant proteins normally localize at the endoplasmic reticulum. However, these two mutations induce a loss of *MTTP* triglyceride transfer activity.

Deleted: *mtp*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTP*Deleted: *MTP*

These two mutations lead to abnormal truncated *MTTP* proteins, incapable of binding *PDI* and responsible for the loss of function of *MTTP*, thereby explaining the severe abetalipoproteinemia phenotype of these children.

Deleted: *MTP*Deleted: *MTP*Deleted: *MTP*Deleted: *MTP*

Keywords: abetalipoproteinemia, *MTTP*, triglyceride transfer, intestinal HDL, endoplasmic reticulum

Deleted: *MTP*

Formatted: Font: Italic

New splicing mutations of *MTTP*

3

Formatted: Font: Italic

INTRODUCTION

Abetalipoproteinemia (ABL, OMIM 200100) is a rare autosomal recessive disease caused by the deficiency of the microsomal triglyceride transfer protein ([MTTP, OMIM 157147](#)). ABL is characterized by the absence of apolipoprotein B (apoB)-containing lipoproteins from plasma. [MTTP](#) is a 97 kDa protein, containing 894 amino acids, that forms a heterodimer with the 55 kDa protein disulfide isomerase (PDI). [MTTP](#) is mainly found in the endoplasmic reticulum (ER) of hepatocytes and enterocytes (Wetterau, et al., 1992).

Deleted: MTP

[MTTP](#) is required for the transfer of neutral lipids to nascent apoB-lipoproteins, resulting in the secretion of very low-density lipoproteins (VLDL) in the liver or chylomicrons (CM) in the intestine. When [MTTP](#) is deficient, nascent apoB is degraded by the proteasome ([Benoist and Grand-Perret, 1997](#)). It differs from familial hypobetalipoproteinemia, displaying dysfunctional apoB and leading to the absence of apoB-lipoproteins in the plasma. Familial hypobetalipoproteinemia is a co-dominant disorder and even if heterozygotes can be asymptomatic, they had low levels of total cholesterol (TC), low density lipoprotein (LDL)-cholesterol and apoB (OMIM 107730).

Deleted: MTP

Deleted: MTP

Formatted: Font: Italic

Deleted: (Zhou, et al., 1998)

ABL was characterized as the consequence of [MTTP](#) absence or dysfunction in 1992 by Wetterau *et al.* (Wetterau, et al., 1992). The genetic defects in [MTTP](#) gene, located on chromosome 4q22-24, were confirmed one year later (Sharp, et al., 1993; Shoulders, et al., 1993). ABL is a very uncommon disease, which highlights the crucial role of this protein. Indeed, the [mttp](#)-deficient mice died at embryonic day 10.5 with abnormal neurological development (exencephalia) (Raabe, et al., 1998). When a specific inducible intestinal deletion of [mttp](#) is generated in mice, they presented a phenotype similar to ABL, with steatorrhea, growth arrest and decreased cholesterol absorption (Xie, et al., 2006).

Deleted: MTP

Deleted: *mttp*

Formatted: Font: Italic

Deleted: MTP

Deleted: MTP

Formatted: Font: Italic

During evolution, [MTTP](#) has progressively acquired TG transfer activity in vertebrates whereas invertebrate [MTTP](#) is known to only transfer phospholipids (Rava and Hussain,

Deleted: MTP

Deleted: MTP

New splicing mutations of *MTTP*

4

Formatted: Font: Italic

2007). Another way to study *MTTP* functions is to characterize human mutations. This

Deleted: MTP

approach could help us to determine its active domains that transfer phospholipids,

cholesterol esters or TG, as well as its binding domains to PDI or to apoB. To our knowledge,

Deleted: lementary

so far, 40 mutations have been described in 52 patients (Supp. [Table S1](#)) (Najah, et al., 2009;

Deleted: table

Zamel, et al., 2008). Here, we report 2 children with a severe form of ABL that are compound

Deleted: MTP

heterozygotes for *MTTP*. The new mutations induce deletion of exon 6 and 10 and translation

Formatted: Font: Italic

of truncated proteins.

For Peer Review

New splicing mutations of *MTTP*

5

Formatted: Font: Italic

MATERIALS AND METHODS

Patients:

We report 2 new cases of ABL, whose diagnosis was performed when AM was a 13 month-old boy and his sister PM was 6 years-old. They were born from Caucasian non-consanguineous parents. We received the agreement of both parents for genetic investigations.

Deleted: ed

Endoscopy and duodenal biopsies:

Upper gastrointestinal endoscopy was realized under general anesthesia with a Pentax EG-1870K. Duodenal biopsies were fixed in Bouin for pathology or immediately frozen in liquid nitrogen for further investigations (Western blot and *MTTP* activity assay). For routine microscopy, biopsies were embedded in paraformaldehyde and sections were hematoxylin/eosin-stained.

Deleted: MTP

Intestinal *MTTP* analyses:

Proteins were extracted from duodenal biopsies to perform a western blot of *MTTP*. *MTTP* activity was measured by radiolabelled TG transfer from donor to acceptor vesicles as previously described (Levy, et al., 2002).

Deleted: MTP

Deleted: MTP

Deleted: MTP

Plasma sample analyses:

Blood samples were collected for lipids, lipoproteins, vitamin A and E investigations, and ALT. TG and TC were measured by an enzymatic method (Roche). HDL and VLDL-cholesterol were measured by a dextran/PEG method (Roche). LDL-cholesterol was calculated by Friedwald method. ApoA-I and apoB were determined by immuno-turbidimetry (Roche).

Lipid chromatography:

The FPLC system consisted of a Hitachi L7250 auto-sampler, a L7100 pump system and two detectors; L7400 (Hitachi) and UVD170U (Dionex). 20µL of plasma were injected and

Deleted: s

Deleted:

New splicing mutations of *MTTP*

6

Formatted: Font: Italic

lipoproteins were separated on SuperoseTM6 10/300GL column (GE Healthcare) with 0.15M NaCl solution at a flow rate of 0.4mL/min. The column effluent was split equally into two lines by a microsplitter 50:50, mixing with cholesterol or triglyceride reagents (Biolabo), thus achieving a simultaneous profile from single injection. The two enzymatic reagents were each pumped at a rate of 0.2mL/min. Both enzymatic reactions proceeded at 37°C in a Teflon reactor coil (15mLx0.4mm id). Proteins were measured directly at 280nm.

Genomic DNA sequencing of *MTTP*:

DNA from patients was extracted from blood samples and then exons and introns of *MTTP* gene (NCBI Reference Sequence: NG_011469.1) were sequenced with Applied ABI Prism.

mRNA sequencing of *MTTP*:

Total RNA was extracted using RNeasy Mini Kit (Qiagen) from either EBV-immortalized B lymphocytes for both children or primary lymphocytes for both children and their parents.

Primary lymphocytes were isolated from blood samples using a ficoll technique. A reverse transcription was performed and nested PCR was used to amplify exon 6 and exon 10 with 5' and 3' flanking regions (see primers in Supp. Table S2). PCR products were separated on agarose gel, then extracted with a QIAquick Gel Extraction Kit (Qiagen) and directly inserted into pCR2.1 vector (Invitrogen) before sequencing analyses.

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Constructs:

WT-MTTP cDNA was a generous gift of Dr M.Hussain (New-York). We produced by PCR *WT-MTTP* and *MTTP* mutants with deletions of patients: *Δ6-MTTP* and *Δ10-MTTP*. PCR fragments (*WT-MTTP*, *Δ6-MTTP* and *Δ10-MTTP*) were digested using BamHI and HindIII restriction enzymes, purified with a QIAquick Gel Extraction Kit (Qiagen) and then inserted

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *mtp*

Formatted: Font: Italic

Deleted:

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: lementary

Deleted: ¶

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTTP*Deleted: *MTTP*

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

New splicing mutations of *MTTP*

7

Formatted: Font: Italic

in pEGFP-N1 or in p2xMyc-N1, generated by replacing the EGFP from pEGFP-N1 with a 2xMyc epitope. pDsRed2-ER vector (Clontech) was used to encode an ER marker.

Cell culture and transfection:

HepG2 (human hepatocellular carcinoma), HeLa (human cervix carcinoma) or Caco-2 (human epithelial colorectal adenocarcinoma) cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 0.1 mM non essential amino acids (Invitrogen), and 100 µg/ml penicillin/streptomycin (Invitrogen) in a humidified atmosphere containing 5% CO₂. HepG2 and HeLa cells were transfected using GenJuice (Novagen, Merck) or Fugene (Roche) respectively.

Immunoprecipitation:

The cells were lysed for 30 min in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10% glycerol) containing protease and phosphatase inhibitors. Soluble material was then incubated overnight at 4°C with 5 µg of monoclonal anti-Myc antibody (clone 9E10) or polyclonal anti-PDI antibody (DL-11). The antigen-antibody complex was incubated with a mix of protein-G and protein-A Sepharose for 1h and then washed in lysis buffer containing 0.1% Nonidet P-40. The bound proteins were eluted by boiling the beads in Laemmli buffer and analyzed by immunoblotting.

Immunoblotting:

The proteins were separated by SDS-polyacrylamide gel electrophoresis under reducing conditions, transferred onto nitrocellulose membrane, and analyzed by immunoblotting according to standard protocols using indicated antibodies. Anti-MTTP antibody was a generous gift of Drs. J. R. Wetterau and H. Jamil. We used a mouse monoclonal antibody against Myc (clone 9E10) from BD Biosciences, a rabbit polyclonal antibody against PDI (DL-11) from Sigma and a mouse monoclonal antibody against GFP from Roche. HRP-labelled secondary antibodies were from Santa-Cruz or Roche Diagnostics.

Deleted: MTP

New splicing mutations of *MTTP*

8

Formatted: Font: Italic

Immunofluorescence experiments:

HepG2 and HeLa cells were grown on collagen I coated or glass coverslips respectively. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.05% saponin, saturated with PBS containing 10% fetal bovine serum and incubated with the anti-PDI rabbit polyclonal antibody (Sigma) or the anti-Golgin 97 mouse monoclonal antibody (Molecular Probes) and then with Cy3-labelled secondary antibody (Jackson Immunoresearch Laboratories). Pictures were captured using a Zeiss LSM 510 META confocal microscope equipped with a 63x Plan-Apochromat objective.

Deleted: first

Deleted: (Molecular Probes)

Immunological investigation:

Serum immunoglobulin levels were determined by nephelometry. B lymphocyte phenotype and function were analyzed as previously described (Peron, et al., 2008).

New splicing mutations of *MTTP*

9

Formatted: Font: Italic

RESULTS

Severe form of abetalipoproteinemia:

When AM was 13-months-old, he presented with a failure to thrive. An intestinal malabsorption was suspected on the basis of abdominal distension, abnormal stools (diarrhea or constipation) and hydro-aeric levels on abdominal X-ray. An upper gastrointestinal endoscopy was performed and revealed a white aspect of duodenal villi characteristic of intestinal fat malabsorption and abnormal lipid storage (Figure 1A), as confirmed by histology (large fat inclusions located within enterocytes, Figure 1B). Blood analyses revealed a severe hypocholesterolemia and hypotriglyceridemia without LDL particles and apoB (Table 1). Since parents have normal lipid values as well as apoB and LDL levels, we ruled out a hypo-betalipoproteinemia which is a dominant inheritance disease. Thus, ABL was suspected. They also had an increased level of alanine amino-transferase (ALT) and a hyperechogenic aspect of the liver on ultra-sound scan. Furthermore, both children presented a severe vitamin E deficiency secondary to intestinal fat malabsorption. His sister (PM), 6-years-old at the time of diagnosis, had no rotula reflex (the very early diagnosis of AM prevented the development of peripheral neuropathy). However, both of them have no sign of retinopathy.

Deleted: o

Deleted: .

Deleted: .

Deleted: As the

Deleted: panels

Deleted: , the

Deleted: of their parents were normal

Deleted: homozygote form of

Deleted: was ruled out

Deleted: and an

Deleted: diagnosed

Abnormal lipoprotein profiles:

We assessed the blood lipoprotein profiles by FPLC analysis. Both children presented a complete absence of LDL and an almost complete absence VLDL in TC and TG moieties (Figure 1C and 1D). Although HDL-cholesterol levels are only 20% of control, HDL particles remain the only lipid class, with a normal ratio of cholesterol ester to TC (Table 1) reflecting a functional lecithin cholesterol acyl-transferase (LCAT) activity. The HDL pattern differs between patient and control. Patient had 2 peaks of HDL particles. The early peak is specific of the patient while the later one appears at the same time than control, as it is suggested by

Deleted: .

Deleted: 2

New splicing mutations of *MTTP*

10

Formatted: Font: Italic

the concordance of protein chromatogram. HDL particles of the early peak seem to be cholesterol-enriched and to have less protein than HDL of the second peak.

Immunoglobulin synthesis abnormalities:

Both of these children had also a congenital hypogammaglobulinemia requiring regular immunoglobulin substitution. They were diagnosed as immunodeficient on serum IgG, IgM and IgA levels that were performed because of a failure to thrive in the first months of age (Table 2). There was no protein losing enteropathy. Mild hypogammaglobulinemia was discovered, affecting IgM and IgG in both children. IgA was also slightly decreased in the brother AM during the first years of age. AM and PM had normal T and B cell populations (data not shown). B cell phenotype was found normal in PM but absence of memory switched B cells was observed in the younger brother AM. In contrast, *in vitro* B cell immunoglobulin production was found normal (data not shown).

MTTP mutations:

Genomic DNA sequencing of *MTTP* gene showed 2 different mutations: c.619G>T and c.1237-28A>G (Supp. Table S3). The first one c.619G>T was located at the first nucleotide of exon 6 and the second one c.1237-28A>G was located within intron 9. In order to understand the consequences of such mutations, we extracted mRNA from lymphocytes and analyzed *MTTP* transcripts. *MTTP* is mainly expressed in the liver and in the intestine, but can also be detected from EBV-immortalized B lymphocytes. After reverse transcription and PCR amplification, products were analyzed by gel migration, thereby revealing a decrease in size for both mutations in patient compared to the control (Figure 2A and 2C). As expected, we obtained in control a band at 228 pb and 888 pb for exons 6 and 10 respectively, whereas lower fragments were revealed in patient. Those fragments were detected at the size of ~90pb and ~780pb, suggesting the loss of exons 6 and 10 respectively. Sequencing confirmed that these two mutations are responsible for abnormal splicing of exons 6 and 10

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *mtp*

Formatted: Font: Italic

Deleted: lementary

Deleted: 3

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *MTTP*

Deleted: cDNA

Deleted: .

Deleted: 3

Deleted: 3B

New splicing mutations of *MTTP* 11

respectively (Figure 2B and 2D). The first genomic DNA mutation c.619G>T induces a frank deletion of exon 6 and a shift in the open reading frame leading to a premature stop codon at position 234 and resulting in an abnormal truncated protein consisting of 233 amino acids (~25kDa). The second DNA mutation c.1237-28A>G induces a frank deletion of exon 10 (36 amino acids), with no shift in the reading frame, leading to a protein of 858 amino acids (~94kDa) (Figure 2E).

These mutations were also confirmed with sequencing analyses from primary lymphocytes from parents and children, meaning that abnormal splicing of *MTTP* was a consequence of genomic mutations and not of EBV immortalization.

As children are compound heterozygotes, these results confirm the genetic diagnosis of ABL.

Loss of function of *MTTP* protein:

Duodenal biopsies were performed and samples were analyzed for *MTTP* expression and activity. In patient, we detected a band with a slight decrease of the apparent *MTTP* size compared to control or Caco-2 cells (Figure 3A), which probably corresponds to $\Delta 10$ -*MTTP* with the loss of 36 amino acids (3kDa) due to exon 10 deletion. We observed no band at a size of 25kDa, corresponding to the expected size of $\Delta 6$ -*MTTP* (data not shown), suggesting that $\Delta 6$ -*MTTP* might be degraded by the proteasome. *MTTP* activity was also measured on these samples and showed a complete loss of TG transfer activity (5-8%/mg protein in control versus 0.08-0.8%/mg protein in AM, Figure 3B).

We further investigated the ability of both $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* mutants to interact with PDI and their subcellular localization by first generating constructs encoding GFP- or 2xMyc-tagged WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP*. Tagged *MTTP* mutants as well as WT-*MTTP* were expressed in HeLa cells and analyzed by immunoblotting. We observed that $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* were detected, as well as WT form (Figure 4A and 4B). This

Formatted: Font: Italic

Deleted: .

Deleted: 3

Deleted: C

Deleted: 3

Deleted: d

Deleted: d

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

Deleted: .

Deleted: 4

Deleted: *MTTP*

Deleted: deletion

Deleted: of the

Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

Deleted: .

Deleted: 4

Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

Deleted: are

Deleted: *MTTP*Deleted: *MTTP*

Deleted: .

Deleted: 5

New splicing mutations of *MTTP* 12

is in contrast to the mutant *MTTP* analysis in duodenal biopsy since $\Delta 6$ -*MTTP* could not be detected. The overexpression level of tagged proteins might overcome the degradation machinery, thereby allowing the detection of a part of $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP*. However, $\Delta 10$ -*MTTP* seemed to be lower expressed compared to WT-*MTTP*, either expressed as GFP- or 2xMyc- $\Delta 10$ -*MTTP* (quantification in Figure 4C), probably because a part of abnormal proteins was degraded by proteasome.

Since *MTTP* is localized in the ER through its binding with PDI, we tested the association of *MTTP* mutants with PDI. 2xMyc-tagged *MTTP* mutant and WT proteins were expressed in both HeLa and HepG2 cells and immunoprecipitation was performed using anti-myc antibody (Figure 4D) or anti-PDI antibody (Figure 4E). As expected, we found that WT-*MTTP* interacted with PDI (Figure 4D and 4E, upper panel). By contrast, neither $\Delta 6$ -*MTTP* nor $\Delta 10$ -*MTTP* was able to associate with PDI (Figure 4D and 4E, middle and lower panels).

We then investigated the cellular localization of WT-*MTTP* as well as $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP*. After expression in both HeLa and HepG2 cells, WT-*MTTP*, $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* displayed an identical pattern, showing a reticular localization throughout the cytosol, reminiscent of ER staining (Supp. Figure S1). However, in HepG2 cells but not in HeLa cells, $\Delta 6$ -*MTTP* also displays a non specific localization both in the nucleus and throughout the cytosol (Supp. Figure S1B, see inset in $\Delta 6$ -*MTTP*-GFP), much like GFP alone. This suggests that in HepG2 cells, $\Delta 6$ -*MTTP*-GFP protein can be degraded, as we observed by immunoblotting in duodenal biopsies. Surprisingly, WT-*MTTP* as well as $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* co-localized with ER markers such as ER-DsRed, a red marker consisting of a fusion of the DsRed and the ER retention sequence, KDEL (Figure 5A) and PDI (Figure 5B). By contrast, no co-localization was observed with cis-Golgi marker such as Golgin 97 (Supp. Figure S2) or trans-Golgi marker such as TGN46 (data not shown).

Formatted: Font: Italic

Deleted: MTP...MTP...MTP...MTP...
MTP...MTP...MTP ... [11]

Deleted: 5 ... [12]

Deleted: MTP...was ...MTP... ... [13]

Deleted: immunoprecipitated

Deleted: MTP

Deleted:6A ... [14]

Deleted: MTP...MTP ... [15]

Deleted: bring down...after
immunoprecipitation6B... ... [16]

Deleted: MTP...MTP...MTP...MTP...
MTP...MTP...lementary ... [17]

Deleted: Fig. 6D and 6E

Deleted: S...MTP...lementary ... [18]

Deleted:6E ... [19]

Deleted: S...MTP...MTP...MTP...MT
P...MTP ... [20]

Deleted: of ER7 ... [21]

Deleted: lementary

Deleted:8 ... [22]

Deleted: S

New splicing mutations of *MTTP*

13

Formatted: Font: Italic

Deleted: MTP

Altogether, these data showed that *MTTP* mutants lost TG transfer activity. They are still localized in the ER despite their inability to interact with PDI.

For Peer Review

New splicing mutations of *MTTP*

14

Formatted: Font: Italic

DISCUSSION

MTTP is mainly expressed in enterocytes and hepatocytes where it participates in the synthesis of chylomicrons and VLDL respectively. These patients presented fat storage in the small intestine (Figure 1A and 1B) and in the liver (as suggested by increased ALT levels and hyperechogenic aspect), as a consequence of *MTTP* dysfunction.

Deleted: MTP

Deleted: .

Deleted: MTP

Lipids are almost exclusively transported in blood into HDL lipoproteins in ABL patients (Figures 1C and 1D and Table 1). These particles are mainly synthesized in peripheral tissues to ensure the reverse cholesterol transport to the liver. But, HDL are also produced at the basolateral membrane of enterocytes, via ATP Binding Cassette-A1 (ABCA1) efflux of cholesterol to apoA-I (Levy, et al., 2007). Cholesterol is transported by enterocytes in two different pathways: the apoB-dependent and the apoB-independent pathways resulting respectively in the production of CM or HDL lipoproteins (Iqbal, et al., 2003). Some differences exist between these two pathways. Cholesterol ester is only secreted within CM while free cholesterol is secreted by both pathways. The apoB-dependent pathway is also regulated by *MTTP* and contributes to cholesterol absorption during post-prandial states.

Deleted: .

Deleted: 2

Deleted: 2

Deleted: 2

Deleted: MTP

Deleted: MTP

MTTP is not required for cholesterol secretion by the apoB-independent pathway that may be more important during fasting states. In the human epithelial Caco-2 cell line, Liver X Receptor/Retinoid X Receptor activation increases *ABCA1* gene expression and basolateral efflux of cholesterol in intestinal HDL (Murthy, et al., 2002). In ABL patients, neurological impairment (ataxia and peripheral neuropathy) and retinopathy are the consequences of vitamin E deficiency. Like cholesterol, these two routes also exist for vitamin E absorption by enterocytes (Anwar, et al., 2007). In *MTTP*-deficient enterocytes, the HDL pathway is used to deliver vitamin E. Vitamin E secretion within HDL lipoproteins is not increased by *MTTP* inhibition (Anwar, et al., 2007). This pathway is not as important as chylomicron synthesis but, in ABL patients, intestinal HDL represent the only route for lipids or vitamin E from

Formatted: Font: Italic

Deleted: MTP

Formatted: Font: Italic

Deleted: MTP

New splicing mutations of *MTTP*

15

Formatted: Font: Italic

intestine to the liver (Anwar, et al., 2007; Anwar, et al., 2006). These ABL patients have a specific class of HDL particles that have a lower density and a lower protein content.

MTTP is also expressed in natural killer T (NKT) cells. Inhibition of *MTTP* in fetal thymocyte organ culture results in a complete loss of NKT cells (Dougan, et al., 2007). In these antigen presenting cells, *MTTP* loads lipids onto nascent CD1d and regulates presentation of glycolipid antigens (Dougan, et al., 2005). *MTTP* deficiency could impair the

recycling of CD1d from lysosome to the plasma membrane (Sagiv, et al., 2007). Interestingly, both patients present with a hypogammaglobulinemia that was mild but however required immunoglobulin substitution. We only found an absence of memory switched B cells in one patient while both of them had a normal *in vitro* immunoglobulin production (Table 2). Since such an association between mild B lymphocyte immunodeficiency and abetalipoproteinemia has not been previously reported in ABL patients, it is unlikely that *MTTP* defect is directly involved in hypogammaglobulinemia. However, this point should be further investigated, looking for a subtle defect in immunoglobulin levels in abetalipoproteinemia patients.

Recently, Zeissig *et al.* characterized the loss of CD1 function in ABL patients (Zeissig, et al., 2010). They found a defect of all antigen-presenting CD1 family members in dendritic cells from ABL patients. Similarly to apoB, *MTTP* deficiency in the ER leads to the degradation of group 1 CD1 by the proteasome pathway, which altered activation of NKT cells.

In these new patients with ABL, we characterized mutations of *MTTP* by analyzing genomic DNA and mRNA products. Sequencing revealed abnormal splicing leading to deletion of exon 6 or 10, as a result of two genomic mutations, c.619G>T and c.1237-28A>G respectively. c.619G>T is not only a missense mutation (207 Val>Phe), but induces as well an abnormal splicing (Mitchell, et al., 1986). The deletion of 140 bp of exon 6 causes a shift in the reading frame and a truncated protein because of a premature stop codon in position 234. Recently, Najah *et al.* (Najah, et al., 2009) found similar results with c.619-3T>G mutation

Deleted: MTP

Deleted: MTP

Deleted: MTP

Deleted: MTP

Deleted: MTP

Formatted: Font: Italic

Deleted: r

Deleted: A

Deleted: MTP

Formatted: Font: Italic

Deleted: 2

New splicing mutations of *MTTP* 16

located in intron 5 of *MTTP*. We showed that this truncated protein is not detected in duodenal biopsies (data not shown), suggesting that $\Delta 6$ -*MTTP* is degraded by the proteasome pathway (Pan, et al., 2007). c.1237-28A>G located in intron 9 leads to the frank deletion of 108 bp of exon 10, with no shift in the reading frame, resulting in the loss of 36 amino acids.

Human *MTTP* structure contains an N-terminal β -barrel (β^N) (residues 22-297), a central α -helical domain (α) (residues 298-603), and two C-terminal β -sheets (β^C and β^A) (residues 604-894). β^N is conserved in apoB, lipovitellin, and apolipoprotein and may be one of the two phospholipid binding sites of *MTTP*. Helices 4-6, β^C and β^A domains of *MTTP* are conserved in vertebrates, but not in invertebrates, suggesting that they are involved in TG transfer activity (Rava and Hussain, 2007). β^N mediates the interaction with the N₂-terminus of apoB; the middle α -helical domain mediates the interaction with both PDI (residues 520-598) and apoB (residues 517-603); and the C-terminal mediates the lipid-binding and transfer catalytic activity of *MTTP* (Mann, et al., 1999; Read, et al., 2000). Expression of *MTTP* constructs in HepG2 and HeLa cells showed that $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* proteins are located at ER (Figure 5) but are not associated with PDI (Figure 4D and 4E). *MTTP* mutants might be retained in the ER as defective or misfolded proteins and a part might be retrotranslocated to the cytosol for proteasomal degradation. The truncated $\Delta 6$ -*MTTP* protein only conserved one apoB-binding domain. By contrast, $\Delta 10$ -*MTTP* protein is characterized by the loss of residues 413-448, that are not directly involved in PDI binding but their loss could alter the tertiary structure of the protein. Finally, these residues, corresponding to helices 7-9 of the central α -helical domain, belong to a critical domain for TG transfer activity as described by Rava and Hussain (Rava and Hussain, 2007).

In conclusion, we report here two new mutations of *MTTP*, c.619G>T and c.1237-28A>G, resulting respectively in $\Delta 6$ -*MTTP* protein, a truncated protein of 233 amino acids and $\Delta 10$ -*MTTP* protein, deleted of exon 10. Despite these mutations do not change ER

Formatted: Font: Italic

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTP*Deleted: *MTP*

Deleted: 2

Deleted: *MTP*...*MTP* (... [23])

Deleted:

Deleted: *MTP*... (Zamel, et al., 2008)...*MTP* (... [24])

Formatted: Font: Italic

Deleted: *MTP*...*MTP* (... [25])

Deleted: ...7...6A...C (... [26])

Deleted: *MTP*...*MTP*...*MTP* (... [27])

Comment [A1]: Reviewer 1 : moved or removed
Reviewer 2 : supprimer jusqu'à la ligne 4 page 16

Deleted: A better understanding of

Deleted: *MTP*

Deleted: *MTTP* regulation could enable us to improve treatment of ABL patients. Moreover, inhibition of

Deleted: *MTP*

Deleted: *MTTP* could be used to lower cholesterol levels in patients with hypercholesterolemia (Cuchel, et (... [28])

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTTP* transcription is (... [29])Deleted: *MTP*Deleted: *MTTP* mRNA when r (... [30])Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTTP* promoter variat (... [31])

Deleted: ed

Deleted: 2

Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTTP* promoter serv (... [32])Deleted: *MTP*Deleted: *MTTP* production, th (... [33])Deleted: *MTP*

Formatted: Font: Italic

Deleted: *MTTP* expression and (... [34])Deleted: *MTP*

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: *MTP*...*MTP*...id (... [35])

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

New splicing mutations of *MTTP*

17

Formatted: Font: Italic

localization of mutant MTTP proteins, they abolish their binding with PDI and totally impaired their TG transfer activity.

Deleted: MTP

Deleted: ed

ACKNOWLEDGEMENTS

The authors thank these children and their parents, and also pediatricians taking care of them (Dr. E. Fournié-Gardini and Dr. A.I. Bertozzi). We also thank J. Bertrand-Michel and V. Roques (Lipidomic Plateau of IFR-BMT/IFR150) for lipidomic analysis, advice and technical assistance. We are grateful to Pr. T. Levade (Toulouse, France) for immortalization of B lymphocytes.

This work was supported by grants from INSERM, ANR (PNRA-2006 ABSINTE) and by grants from Canadian Institutes of Health Research, MOP 10584 (E.L). V.P and E.M were the recipients of a fellowship from the Fondation pour la Recherche Médicale. V.P is a young researcher with temporary contract from INSERM. X.C was a recipient of a “Contrat d’Interface” from CHU of Toulouse.

New splicing mutations of *MTTP*

18

Formatted: Font: Italic

Deleted: Immunoglobulin levels of both patients were reported at the diagnosis of hypogammaglobulinemia, just after the diagnosis of abetalipoproteinemia and at the last follow-up.

Deleted: TABLES¶
¶
Table 1. Biochemical diagnosis of abetalipoproteinemia

Deleted: ¶ ... [36]

Deleted: Table 2. Immunoglobulin levels¶
... [37]

Formatted: English U.K.

Formatted Table

Deleted: ¶

Deleted: ¶
-----Page Break-----

Comment [A2]: Reviewer 2 : supplementary data

Deleted: ¶
Table 3. Genomic mutations of

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *MTTP*

Deleted: Titles and legends to figures

Deleted: ¶ ... [38]

Formatted: English U.K.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

FIGURES LEGENDS

Figure 1. Diagnosis of abetalipoproteinemia

(A) Upper gastrointestinal endoscopy performed in patient AM revealed a white aspect of duodenal villi, characteristic of lipid storage. (B) Biopsy was performed in duodenum and processed for hematoxylin/eosin-staining. The arrow points at the presence of lipid droplets within the enterocytes. (C and D) Serum from control or patient (AM) was analyzed using FPLC system. Lipoproteins were separated and total cholesterol (C) and triglycerides (D) were measured. Profiles are shown for control (Ctrl) and patient (AM). Proteins were only showed for patient in C. Note the difference of y-axis (lipid content) between control and patient.

Deleted: ¶
¶
Figure 2. Blood lipid analysis ¶

Deleted: A

Deleted: B

Deleted: were

Deleted: A

Deleted: B

Deleted: A

Figure 2. Sequence analysis of mutant *MTTP* transcription products

(A and C) After mRNA extraction and reverse transcription from control and patient (AM) EBV-immortalized lymphocytes, PCR was performed to amplify exon 6 (A) and exon 10 (C) with 5' and 3' flanking regions. PCR products were analyzed by migration on agarose gel. Arrowhead points at the lower band found in patient compared to the control. (B and D) Upper bands in the control and lower bands in patients were purified and then cloned into pCR2.1 vector before sequencing. In (B), electrophoregrams showed the exon 6 and 5' and 3' flanking regions with exon 5 and 7 in the control. In the patient, the exon 6 is deleted, leading to a frameshift and a premature stop codon. In (D), similarly, electrophoregrams showed the exon 10 and 5' and 3' flanking regions with exon 9 and 11 in the control. In the patient, the exon 10 is deleted. (E) The amino acid sequences corresponding to exons 6 and 10 are shown underlined and in blue in the normal *MTTP* sequence. // determined the deletion of exons 6 or

Deleted: 3

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: B

Deleted: B

Deleted: C

Deleted: C

New splicing mutations of *MTTP*

20

Formatted: Font: Italic

Formatted: Font: Not Italic

10 in each mutant. For $\Delta 6$ -*MTTP*, the frame-shift mutation results in an abnormal sequence described in red and in italic.

Deleted:

Deleted: ¶

Deleted: 4

Deleted: *MTTP*

Figure 3. *MTTP* expression and activity in duodenal biopsy

(A) Duodenal biopsy from control (Ctrl) or patient (AM) and Caco-2 cell lysate were analyzed by SDS gel electrophoresis and western blotting with antibodies against *MTTP*. (B) The triglyceride transfer activity of *MTTP* was measured on duodenal biopsy from control or patient (AM). Values are expressed as the mean of three independent experiments; standard errors are indicated.

Deleted: *MTTP*Deleted: *MTTP*

Deleted: (Ctrl)

Figure 4. Interaction of WT and mutant *MTTP* with PDI

(A and B) HeLa cells were transfected or not with WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP* tagged with EGFP (A) or 2xMyc (B). Cell lysates (100 μ g) were analyzed by SDS gel electrophoresis and western blotting with antibodies against GFP (A), Myc (B) and Rab5 as loading control. Arrowheads point at WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP* and arrows point at non specific band (ns). Blots in (B) were scanned and the quantification is shown in (C). Each experiment was repeated at least 3 times, and (C) shows a representative example. (D and E) HeLa cells were transfected with 2xMyc-tagged WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP*. Cell lysates (Lys) were subjected to immunoprecipitation with (+) or without (-) the anti-myc antibody (D) or the anti-PDI antibody (E). Analysis was performed by SDS gel electrophoresis and western blotting with antibodies against Myc or PDI. Arrowheads point at immunoprecipitated WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP* (D) or PDI (E) and arrows point at non specific band (ns). IgG HC represents heavy chain of anti-PDI antibody used for immunoprecipitation.

Deleted: 5

Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Deleted: WT and mutant

Deleted: *MTTP*

Formatted: Font: Not Bold, Italic

Deleted: *MTTP* expression in HeLa cells¶Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

Deleted: ¶

¶ Figure 6. Interaction of WT and mutant

Deleted: *MTTP*

Formatted: Font: Italic

Deleted: *MTTP* with PDI¶ (A-C)Deleted: *MTTP*

Deleted: (A)

Deleted: *MTTP*

Deleted: (B)

Deleted: *MTTP*

Deleted: (C)

Deleted: : 5% of total

Deleted: *MTTP*Deleted: *MTTP*Deleted: *MTTP*

New splicing mutations of *MTTP*

21

Figure 5. Localization of WT and mutant *MTTP* and ER marker

(A) HeLa cells were co-transfected with GFP-tagged WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP* and a vector encoding DsRed-ER marker. Cells were then processed for fluorescence analysis. (B) HeLa cells were transfected with GFP-tagged WT-*MTTP*, $\Delta 6$ -*MTTP* or $\Delta 10$ -*MTTP* and were then processed for immunofluorescence using anti-PDI antibody. Bar: 10 μ m.

- Formatted: Font: Italic
- Deleted: (D and E) HeLa cells (D) or hepG2 cells (E) were transfected with GFP-tagged WT-
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP*, $\Delta 6$ -
- Deleted: *MTTP*
- Deleted: *MTTP* or $\Delta 10$ -
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP*. Cells were then processed for fluorescence analysis. Bar: 10 μ m.
- Deleted: 7
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP*
- Deleted: *MTTP*
- Deleted: *MTTP*
- Formatted: Font: Italic
- Formatted: Font: Not Italic
- Formatted: Font: Not Italic
- Formatted: Font: Not Italic
- Deleted: ¶
Figure 8. Localization of WT and mutant
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP*. Cells were then processed for immunofluorescence using anti-golgin 97 antibody and analyzed. Bar: 10 μ m.
- Deleted: ¶
¶
¶
- Formatted: Font: Italic
- Deleted: *MTTP* and Golgi marker¶
HeLa cells were transfected with GFP-tagged WT-
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP*, $\Delta 6$ -
- Deleted: *MTTP*
- Formatted: Font: Italic
- Deleted: *MTTP* or $\Delta 10$ -
- Deleted: *MTTP*

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- [Al-Shali K, Wang J, Rosen F, Hegele RA. 2003. Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia. Clin Genet 63\(2\):135-8.](#)
- [Anwar K, Iqbal J, Hussain MM. 2007. Mechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption. J Lipid Res 48\(9\):2028-38.](#)
- [Anwar K, Kayden HJ, Hussain MM. 2006. Transport of vitamin E by differentiated Caco-2 cells. J Lipid Res 47\(6\):1261-73.](#)
- [Au WS, Lu L, Yeung CM, Liu CC, Wong OG, Lai L, Kung HF, Lin MC. 2008. Hepatocyte nuclear factor 1 binding element within the promoter of microsomal triglyceride transfer protein \(MTTP\) gene is crucial for MTTP basal expression and insulin responsiveness. J Mol Endocrinol 41\(4\):229-38.](#)
- [Benayoun L, Granot E, Rizel L, Allon-Shalev S, Behar DM, Ben-Yosef T. 2007. Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi Jewish population and a contiguous gene deletion in an Arab patient. Mol Genet Metab 90\(4\):453-7.](#)
- [Benoist F, Grand-Perret T. 1997. Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. J Biol Chem 272\(33\):20435-42.](#)
- [Berthier MT, Couture P, Houde A, Paradis AM, Sammak A, Verner A, Depres JP, Gagne C, Gaudet D, Vohl MC. 2004. The c.419-420insA in the MTP gene is associated with abetalipoproteinemia among French-Canadians. Mol Genet Metab 81\(2\):140-3.](#)
- [Chardon L, Sassolas A, Digeon B, Michel-Calemard L, Bovier-Lapierre M, Moulin P, Lachaux A. 2008. Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases. Eur J Pediatr.](#)
- [Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE and others. 2007. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356\(2\):148-56.](#)
- [Di Leo E, Lancellotti S, Penacchioni JY, Cefalu AB, Averna M, Pisciotta L, Bertolini S, Calandra S, Gabelli C, Tarugi P. 2005. Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis 180\(2\):311-8.](#)
- [Dische MR, Porro RS. 1970. The cardiac lesions in Bassen-Kornzweig syndrome. Report of a case, with autopsy findings. Am J Med 49\(4\):568-71.](#)

Formatted: Font: Italic**Deleted:** SUPPLEMENTARY INFORMATION¶

¶ Supplementary Table 1. Description of MTP mutations reported in the literature¶

Deleted: ¶**Deleted:** ¶ Supplementary Table 2. PCR primers¶¶ Supplementary Table 3. Genomic mutations of *MTTP* ¶**Formatted:** Font: Italic**Deleted:** Supplementary Figure 1. MTP translation products¶The amino acids corresponding to exon 6 and 10 are underlined in the normal *MTP* sequence. // determined the deletion of exon 6 or 10. For $\Delta 6$ -*MTP*, the frame-shift mutation results in an abnormal sequence described in red and in italic.¶**Formatted:** Font: Italic**Formatted:** Font: Italic**Deleted:** Supplementary Figure S1: Localization of WT and mutant MTTP¶HeLa cells (A) or HepG2 cells (B) were transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and were then processed for immunofluorescence. Bar: 10 μ m.¶**Deleted:** Supplementary Figure S2: Localization of WT and mutant MTTP and Golgi marker¶HeLa cells were transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and were then processed for immunofluorescence using anti-Golgin 97 antibody. Bar: 10 μ m

.....Page Break.....

Formatted: Font: Italic**Formatted:** German Germany**Formatted:** Font: Not Bold**Formatted:** Justified, Line spacing: 1.5 lines

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Dougan SK, Rava P, Hussain MM, Blumberg RS. 2007. MTP regulated by an alternate promoter is essential for NKT cell development. J Exp Med 204\(3\):533-45.](#)
- [Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, Khurana A, Kronenberg M, Johnson C, Exley M and others. 2005. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 202\(4\):529-39.](#)
- [Heath KE, Luong LA, Leonard JV, Chester A, Shoulders CC, Scott J, Middleton-Price HR, Humphries SE, Talmud PJ. 1997. The use of a highly informative CA repeat polymorphism within the abetalipoproteinaemia locus \(4q22-24\). Prenat Diagn 17\(12\):1181-6.](#)
- [Iqbal J, Anwar K, Hussain MM. 2003. Multiple, independently regulated pathways of cholesterol transport across the intestinal epithelial cells. J Biol Chem 278\(34\):31610-20.](#)
- [Iqbal J, Dai K, Seimon T, Jungreis R, Oyadomari M, Kuriakose G, Ron D, Tabas I, Hussain MM. 2008. IRE1beta inhibits chylomicron production by selectively degrading MTP mRNA. Cell Metab 7\(5\):445-55.](#)
- [Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. 2008. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118\(6\):2347-64.](#)
- [Levy E, Spahis S, Sinnott D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. 2007. Intestinal cholesterol transport proteins: an update and beyond. Curr Opin Lipidol 18\(3\):310-8.](#)
- [Levy E, Stan S, Delvin E, Menard D, Shoulders C, Garofalo C, Slight I, Seidman E, Mayer G, Bendayan M. 2002. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J Biol Chem 277\(19\):16470-7.](#)
- [Mitchell PJ, Urlaub G, Chasin L. 1986. Spontaneous splicing mutations at the dihydrofolate reductase locus in Chinese hamster ovary cells. Mol Cell Biol 6\(6\):1926-35.](#)
- [Murthy S, Born E, Mathur SN, Field FJ. 2002. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res 43\(7\):1054-64.](#)
- [Najah M, Di Leo E, Awatef J, Magnolo L, Imene J, Pinotti E, Bahri M, Barsaoui S, Brini I, Fekih M and others. 2009. Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia. Clin Chim Acta 401\(1-2\):51-6.](#)
- [Narcisi TM, Shoulders CC, Chester SA, Read J, Brett DJ, Harrison GB, Grantham TT, Fox MF, Povey S, de Bruin TW and others. 1995. Mutations of the microsomal](#)

[triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet 57\(6\):1298-310.](#)

[Ohashi K, Ishibashi S, Osuga J, Tozawa R, Harada K, Yahagi N, Shionoiri F, Iizuka Y, Tamura Y, Nagai R and others. 2000. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res 41\(8\):1199-204.](#)

[Pan X, Hussain FN, Iqbal J, Feuerman MH, Hussain MM. 2007. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem 282\(23\):17078-89.](#)

[Peron S, Metin A, Gardes P, Alyanakian MA, Sheridan E, Kratz CP, Fischer A, Durandy A. 2008. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 205\(11\):2465-72.](#)

[Raabe M, Flynn LM, Zlot CH, Wong JS, Veniant MM, Hamilton RL, Young SG. 1998. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A 95\(15\):8686-91.](#)

[Rava P, Hussain MM. 2007. Acquisition of triacylglycerol transfer activity by microsomal triglyceride transfer protein during evolution. Biochemistry 46\(43\):12263-74.](#)

[Rehberg EF, Samson-Bouma ME, Kienzle B, Blinderman L, Jamil H, Wetterau JR, Aggerbeck LP, Gordon DA. 1996. A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase. J Biol Chem 271\(47\):29945-52.](#)

Formatted: German Germany

[Ricci B, Sharp D, O'Rourke E, Kienzle B, Blinderman L, Gordon D, Smith-Monroy C, Robinson G, Gregg RE, Rader DJ and others. 1995. A 30-amino acid truncation of the microsomal triglyceride transfer protein large subunit disrupts its interaction with protein disulfide-isomerase and causes abetalipoproteinemia. J Biol Chem 270\(24\):14281-5.](#)

[Sagiv Y, Bai L, Wei DG, Agami R, Savage PB, Teyton L, Bendelac A. 2007. A distal effect of microsomal triglyceride transfer protein deficiency on the lysosomal recycling of CD1d. J Exp Med 204\(4\):921-8.](#)

[Sakamoto O, Ohura T, Matsubara Y, Takayanagi M, Tsuchiya S. 2007. Mutation and haplotype analyses of the MUT gene in Japanese patients with methylmalonic acidemia. J Hum Genet 52\(1\):48-55.](#)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Schgoer W, Eller P, Mueller T, Tancevski I, Wehinger A, Ulmer H, Sandhofer A, Ritsch A, Haltmayer M, Patsch JR. 2008. The MTP -493TT genotype is associated with peripheral arterial disease: results from the Linz Peripheral Arterial Disease \(LIPAD\) Study. Clin Biochem 41\(9\):712-6.](#)
- [Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ and others. 1993. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365\(6441\):65-9.](#)
- [Sheena V, Hertz R, Nousbeck J, Berman I, Magenheim J, Bar-Tana J. 2005. Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4alpha. J Lipid Res 46\(2\):328-41.](#)
- [Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, Leoni PR, Bhattacharya S, Pease RJ, Cullen PM and others. 1993. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet 2\(12\):2109-16.](#)
- [Vongsuvan R, Hooper AJ, Coakley JC, Macdessi JS, O'Loughlin EV, Burnett JR, Gaskin KJ. 2007. Novel mutations in abetalipoproteinaemia and homozygous familial hypobetalipoproteinaemia. J Inher Metab Dis 30\(6\):990.](#)
- [Wang J, Hegele RA. 2000. Microsomal triglyceride transfer protein \(MTP\) gene mutations in Canadian subjects with abetalipoproteinemia. Hum Mutat 15\(3\):294-5.](#)
- [Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258\(5084\):999-1001.](#)
- [Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, Luo J, Kennedy S, Davidson NO. 2006. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mtp deficiency. J Biol Chem 281\(7\):4075-86.](#)
- [Yang XP, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H. 1999. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler Thromb Vasc Biol 19\(8\):1950-5.](#)
- [Zamel R, Khan R, Pollex RL, Hegele RA. 2008. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis 3:19.](#)
- [Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, Ruggiero G, Adinolfi LE. 2008. Microsomal triglyceride transfer protein \(MTP\) -](#)

New splicing mutations of *MTTP*

26

Formatted: Font: Italic

[493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat 15\(10\):740-6.](#)

[Zhou M, Fisher EA, Ginsberg HN. 1998. Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J Biol Chem 273\(38\):24649-53.](#)

[Zeissig S, Dougan SK, Barral DC, Junker Y, Chen Z, Kaser A, Ho M, Mandel H, McIntyre A, Kennedy SM and others. 2010. Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest 120\(8\):2889-99.](#)

Formatted: Font: Not Bold

Formatted: Justified, Line spacing: 1.5 lines

Formatted: Font: Not Bold

For Peer Review

1
2
3 **Page 1: [1] Deleted** PONS 1/31/2011 12:04:00 PM

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2
3 **Page 1: [1] Deleted** PONS 1/31/2011 12:04:00 PM

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7 **Page 1: [2] Deleted** Administrateur 2/7/2011 8:38:00 AM

1, **Page 1: [2] Deleted** Administrateur 1/31/2011 11:40:00 AM

2 **Page 1: [3] Deleted** PONS 1/31/2011 12:06:00 PM

7 **Page 1: [3] Deleted** PONS 1/31/2011 12:06:00 PM

Page 1: [4] Deleted Administrateur 1/31/2011 11:36:00 AM

U563

Page 1: [4] Deleted Administrateur 2/7/2011 8:31:00 AM

Page 1: [5] Formatted Administrateur 2/7/2011 8:41:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France, Not Highlight

Page 1: [5] Formatted Administrateur 2/7/2011 8:41:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France

Page 1: [5] Formatted Administrateur 2/7/2011 8:41:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France, Not Highlight

Page 1: [5] Formatted Administrateur 2/7/2011 8:41:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France

Page 1: [6] Formatted Administrateur 2/7/2011 8:40:00 AM

Font: (Default) Times New Roman, (Asian) Times New Roman, Complex Script Font: Times New Roman, French France

Page 1: [6] Formatted Administrateur 2/7/2011 8:40:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French France

Page 1: [7] Formatted Administrateur 2/7/2011 8:40:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman

Page 1: [7] Formatted Administrateur 2/7/2011 8:40:00 AM

Font: (Default) Times New Roman, Complex Script Font: Times New Roman, French
France

Page 1: [8] Deleted **Administrateur** **2/7/2011 8:38:00 AM**

Page 1: [8] Deleted **Administrateur** **1/31/2011 11:17:00 AM**

Page 1: [9] Formatted **Administrateur** **2/7/2011 8:40:00 AM**

Font: (Default) Times New Roman, 12 pt, Font color: Auto, Complex Script Font: Times
New Roman, 12 pt

Page 1: [9] Formatted **Administrateur** **2/7/2011 8:40:00 AM**

Font: (Default) Times New Roman, 12 pt, Font color: Auto, Complex Script Font: Times
New Roman, 12 pt

Page 1: [10] Deleted **Administrateur** **2/7/2011 8:38:00 AM**

Page 1: [10] Deleted **Administrateur** **2/7/2011 8:33:00 AM**

Hôpital des Enfants,

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [11] Deleted **Administrateur** **1/3/2011 12:26:00 PM**

MTP

Page 12: [12] Deleted **PONS** **1/28/2011 6:13:00 PM**

1
2
3
4
5
6
7 **Page 12: [12] Deleted** PONS 1/28/2011 5:08:00 PM

8 5

9
10
11 **Page 12: [13] Deleted** Administrateur 1/3/2011 12:26:00 PM

12 MTP

13
14
15 **Page 12: [13] Deleted** Administrateur 2/7/2011 9:12:00 AM

16 was

17
18
19 **Page 12: [13] Deleted** Administrateur 1/3/2011 12:26:00 PM

20 MTP

21
22
23 **Page 12: [13] Deleted** Administrateur 1/3/2011 12:26:00 PM

24 MTP

25
26
27 **Page 12: [14] Deleted** PONS 1/28/2011 6:13:00 PM

28
29
30
31
32 **Page 12: [14] Deleted** PONS 1/28/2011 5:09:00 PM

33 6A

34
35
36 **Page 12: [15] Deleted** Administrateur 1/3/2011 12:26:00 PM

37 MTP

38
39
40 **Page 12: [15] Deleted** Administrateur 1/3/2011 12:26:00 PM

41 MTP

42
43
44 **Page 12: [16] Deleted** PONS 1/28/2011 5:09:00 PM

45 bring down

46
47
48 **Page 12: [16] Deleted** PONS 1/28/2011 5:10:00 PM

49 after immunoprecipitation

50
51
52 **Page 12: [16] Deleted** PONS 1/28/2011 6:13:00 PM

53
54
55
56
57 **Page 12: [16] Deleted** PONS 1/28/2011 5:10:00 PM

1
2
3 6B
4
5
6

7 **Page 12: [16] Deleted** PONS 1/28/2011 5:10:00 PM

8 6C
9

10 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

11 MTP
12

13 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

14 MTP
15

16 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

17 MTP
18

19 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

20 MTP
21

22 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

23 MTP
24

25 **Page 12: [17] Deleted** Administrateur 1/3/2011 12:26:00 PM

26 MTP
27

28 **Page 12: [17] Deleted** Administrateur 2/7/2011 10:28:00 AM

29 lementary
30

31 **Page 12: [18] Deleted** Administrateur 2/7/2011 9:13:00 AM

32 S
33

34 **Page 12: [18] Deleted** Administrateur 1/3/2011 12:26:00 PM

35 MTP
36

37 **Page 12: [18] Deleted** Administrateur 2/7/2011 10:28:00 AM

38 lementary
39

40 **Page 12: [19] Deleted** PONS 1/28/2011 6:13:00 PM

41 .
42

43 **Page 12: [19] Deleted** PONS 1/28/2011 5:14:00 PM
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

6E

Page 12: [20] Deleted	Administrateur	2/7/2011 9:13:00 AM
-----------------------	----------------	---------------------

S

Page 12: [20] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 12: [20] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 12: [20] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 12: [20] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 12: [20] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 12: [21] Deleted	PONS	1/28/2011 5:15:00 PM
-----------------------	------	----------------------

of ER

Page 12: [21] Deleted	PONS	1/28/2011 6:15:00 PM
-----------------------	------	----------------------

Page 12: [21] Deleted	PONS	1/28/2011 5:15:00 PM
-----------------------	------	----------------------

7

Page 12: [22] Deleted	PONS	1/28/2011 6:15:00 PM
-----------------------	------	----------------------

Page 12: [22] Deleted	PONS	1/28/2011 5:16:00 PM
-----------------------	------	----------------------

8

Page 16: [23] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

MTP

Page 16: [23] Deleted	Administrateur	1/3/2011 12:26:00 PM
-----------------------	----------------	----------------------

1
2
3 MTP
4
5

6 **Page 16: [24] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

7 MTP
8
9

10 **Page 16: [24] Deleted** **Administrateur** **1/10/2011 1:07:00 PM**

11 (Zamel, et al., 2008)
12
13

14 **Page 16: [24] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

15 *MTP*
16
17

18 **Page 16: [25] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

19 MTP
20
21

22 **Page 16: [25] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

23 MTP
24
25

26 **Page 16: [26] Deleted** **PONS** **1/28/2011 6:17:00 PM**

27 .
28
29

30 **Page 16: [26] Deleted** **PONS** **1/28/2011 6:17:00 PM**

31 7
32
33

34 **Page 16: [26] Deleted** **PONS** **1/28/2011 6:18:00 PM**

35 .
36
37

38 **Page 16: [26] Deleted** **PONS** **1/28/2011 6:17:00 PM**

39 6A
40
41

42 **Page 16: [26] Deleted** **PONS** **1/28/2011 6:18:00 PM**

43 -C
44
45

46 **Page 16: [27] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

47 MTP
48
49

50 **Page 16: [27] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

51 MTP
52
53

54 **Page 16: [27] Deleted** **Administrateur** **1/3/2011 12:26:00 PM**

55
56
57
58
59
60

1
2
3 MTP
4
5

6 **Page 16: [28] Deleted** **PONS** **1/31/2011 5:23:00 PM**

7 MTP could be used to lower cholesterol levels in patients with
8 hypercholesterolemia (Cuchel, et al., 2007). However, adverse events like liver steatosis
9 or vitamin E deficiency should be prevented.
10
11
12

13
14
15 **Page 16: [29] Deleted** **PONS** **1/31/2011 5:23:00 PM**

16 *MTP* transcription is controlled by hepatocyte nuclear factor-4 α (HNF-4 α)
17 (Sheena, et al., 2005). Hepatocyte nuclear factor binding element (HNF1A) within the
18
19
20

21
22 **Page 16: [30] Deleted** **PONS** **1/31/2011 5:23:00 PM**

23 *MTP* mRNA when mice are fed with high-cholesterol and high-fat diets (Iqbal,
24 et al., 2008). The
25
26
27

28
29 **Page 16: [31] Deleted** **PONS** **1/31/2011 5:23:00 PM**

30 *MTP* promoter variant -579T/T is associated with peripheral arterial disease
31 (Schgoer, et al., 2008). The -579G/T polymorphism contributes to fat liver accumulation
32 in 3 infected patients with HCV genotype (Zampino, et al., 2008), but could also have a
33 role in the steatosis of these children.[A1]
34
35
36
37
38

39 **Page 16: [32] Deleted** **PONS** **1/31/2011 5:23:00 PM**

40 *MTP* promoter serves as a novel negative insulin-responsive element (Au, et al.,
41 2008). Forkhead box O1 (FoxO1) mediates insulin-regulated
42
43
44
45

46 **Page 16: [33] Deleted** **PONS** **1/31/2011 5:23:00 PM**

47 MTP production, that may be a causative factor for VLDL overproduction and
48 hypertriglyceridemia in diabetes (Kamagate, et al., 2008). Regulation of
49
50
51

52
53 **Page 16: [34] Deleted** **PONS** **1/31/2011 5:23:00 PM**

54 *MTP* expression and CM production is controlled by inositol-requiring enzyme
55 1beta (IRE1beta), which degrades
56
57
58
59
60

Page 16: [35] Deleted Administrateur 1/3/2011 12:26:00 PM

MTP

Page 16: [35] Deleted Administrateur 1/3/2011 12:26:00 PM

MTP

Page 16: [35] Deleted Administrateur 2/7/2011 9:39:00 AM

id

Page 18: [36] Deleted Administrateur 2/7/2011 10:18:00 AM

	AM	PM	Children Normal Range	Father	Mother	Adults Normal Range
Triglycerides	6	1	< 75 mg/dL	77	87	50-150 mg/dL
Total cholesterol	30	30	< 170 mg/dL	166	235	105-240 mg/dL
HDL-cholesterol	29	30	> 40 mg/dL	46	69	40-80 mg/dL
VLDL-cholesterol	10	0	ND	16	17	10-30 mg/dL
LDL-cholesterol	0	0	< 110 mg/dL	105	148	108-162 mg/dL
ApoA-I	0.43	0.48	NA	1.25	1.71	1.1-2.1 g/L
Apo-B	0.02	0.01	< 90 mg/dL	0.68	0.92	0.5-1.35 g/L
Retinol/RBP	0.68	1.06	0.95-1.06	ND	ND	
Tocopherol	0.41	0.16	6-15 mg/L	ND	ND	

NA: no available; ND: not done.

Page 18: [37] Deleted Administrateur 2/7/2011 10:18:00 AM

	AM, born the 21/01/2004	PM, born the 25/07/1999	
--	--------------------------------	--------------------------------	--

	29/04/2004	11/10/2005	27/07/2010	30/09/1999	29/11/2005	27/07/2010	Normal range
IgG	0.95	7.86	6.48	0.33	8.63	5.47	5.6 - 10.4 g/L
IgA	0.04	0.11	1.11	0.02	1.73	1.67	0.4 - 1.4 g/L
IgM	0.11	0.67	0.73	0.04	0.44	0.36	0.6 - 1.6 g/L

Page 18: [38] Deleted

PONS

1/31/2011 5:29:00 PM

	exon 6 deletion	exon 10 deletion
AM	c.619G>T	c.1237-28A>G
PM	c.619G>T	c.1237-28A>G
Father	c.619G>T	normal
Mother	normal	c.1237-28A>G

1 New splicing mutations of *MTTP*

2
3 **A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal**
4 **triglyceride transfer protein**
5
6

7
8 Véronique Pons ^{1,2}, Corinne Rolland ^{3,4}, Michel Nauze ^{1,2}, Marie Danjoux ⁵, Gérald Gaibelet
9 ^{1,2}, Anne Durandy ⁶, Agnès Sassolas ⁷, Emile Lévy ⁸, François Tercé ^{1,2}, Xavier Collet ^{1,2*}
10 and Emmanuel Mas ^{3,4,9*}
11
12

13
14
15 ¹INSERM, U1048, Toulouse, F-31000, France;

16
17 ²Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse,
18 F-31300 France;

19
20 ³INSERM, U1043, Toulouse, F-31300 France;

21
22 ⁴Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP),
23 Toulouse, F-31300, France;

24
25 ⁵CHU Toulouse, Hôpital Purpan, Département d'Anatomopathologie, Toulouse, F-31300
26 France;

27
28 ⁶INSERM U768, Université Paris V-René Descartes, Hôpital Necker-Enfants Malades, 75015
29 Paris (France);

30
31 ⁷UF Dyslipidémies, CBPE, Hospices Civils de Lyon and Lyon University, INSERM U1060,
32 CarMeN Laboratory, Univ Lyon-1 F-69621, Villeurbanne (France);

33
34 ⁸Départements de Nutrition et de Biochimie, Hôpital Sainte-Justine et Université de Montréal,
35 Montréal, Québec (Canada);

36
37 ⁹CHU Toulouse, Hôpital des Enfants, Unité de Gastroentérologie, Hépatologie et Nutrition,
38 Département de Pédiatrie, Toulouse, F-31300, France.

39
40 * These authors equally contributed to the work
41
42
43

44
45
46
47 **Corresponding author:**

48 Emmanuel Mas, MD

49 Hôpital des Enfants - Unité de Gastroentérologie, Hépatologie et Nutrition – 330 avenue de
50 Grande-Bretagne – TSA 70034 – 31059 Toulouse cedex 9 (France)

51 Tel. (33) 5 34 55 84 45

52 Fax. (33) 5 34 55 85 67

53 E-mail: mas.e@chu-toulouse.fr
54
55
56
57
58
59
60

ABSTRACT

Abetalipoproteinemia is a rare autosomal recessive disease characterized by low lipid levels and by the absence of apoB-containing lipoproteins. It is the consequence of microsomal triglyceride transfer protein (MTTP) deficiency.

We report 2 patients with new *MTTP* mutations. We studied their functional consequences on the triglyceride transfer function using duodenal biopsies. We transfected *MTTP* mutants in HepG2 and HeLa cells to investigate their association with protein disulfide isomerase (*PDI*) and their localization at the endoplasmic reticulum.

These children have a severe abetalipoproteinemia. Both of them had also a mild hypogammaglobulinemia. They are compound heterozygotes with c.619G>T and c.1237-28A>G mutations within *MTTP* gene. mRNA analysis revealed abnormal splicing with deletion of exon 6 and 10, respectively. Deletion of exon 6 ($\Delta 6$ -*MTTP*) introduced a frame shift in the reading frame and a premature stop codon at position 234. Despite $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* mutants were not capable of binding PDI, both MTTP mutant proteins normally localize at the endoplasmic reticulum. However, these two mutations induce a loss of MTTP triglyceride transfer activity.

These two mutations lead to abnormal truncated MTTP proteins, incapable of binding PDI and responsible for the loss of function of MTTP, thereby explaining the severe abetalipoproteinemia phenotype of these children.

Keywords: abetalipoproteinemia, *MTTP*, triglyceride transfer, intestinal HDL, endoplasmic reticulum

INTRODUCTION

Abetalipoproteinemia (ABL, OMIM 200100) is a rare autosomal recessive disease caused by the deficiency of the microsomal triglyceride transfer protein (MTTP, OMIM 157147). ABL is characterized by the absence of apolipoprotein B (apoB)-containing lipoproteins from plasma. MTTP is a 97 kDa protein, containing 894 amino acids, that forms a heterodimer with the 55 kDa protein disulfide isomerase (PDI). MTTP is mainly found in the endoplasmic reticulum (ER) of hepatocytes and enterocytes (Wetterau, et al., 1992). MTTP is required for the transfer of neutral lipids to nascent apoB-lipoproteins, resulting in the secretion of very low-density lipoproteins (VLDL) in the liver or chylomicrons (CM) in the intestine. When *MTTP* is deficient, nascent apoB is degraded by the proteasome (Benoist and Grand-Perret, 1997). It differs from familial hypobetalipoproteinemia, displaying dysfunctional apoB and leading to the absence of apoB-lipoproteins in the plasma. Familial hypobetalipoproteinemia is a co-dominant disorder and even if heterozygotes can be asymptomatic, they had low levels of total cholesterol (TC), low density lipoprotein (LDL)-cholesterol and apoB (OMIM 107730).

ABL was characterized as the consequence of MTTP absence or dysfunction in 1992 by Wetterau *et al.* (Wetterau, et al., 1992). The genetic defects in *MTTP* gene, located on chromosome 4q22-24, were confirmed one year later (Sharp, et al., 1993; Shoulders, et al., 1993). ABL is a very uncommon disease, which highlights the crucial role of this protein. Indeed, the *mttp*-deficient mice died at embryonic day 10.5 with abnormal neurological development (exencephalia) (Raabe, et al., 1998). When a specific inducible intestinal deletion of *mttp* is generated in mice, they presented a phenotype similar to ABL, with steatorrhea, growth arrest and decreased cholesterol absorption (Xie, et al., 2006).

During evolution, MTTP has progressively acquired TG transfer activity in vertebrates whereas invertebrate MTTP is known to only transfer phospholipids (Rava and Hussain,

New splicing mutations of *MTTP*

4

1
2
3 2007). Another way to study MTTP functions is to characterize human mutations. This
4
5 approach could help us to determine its active domains that transfer phospholipids,
6
7 cholesterol esters or TG, as well as its binding domains to PDI or to apoB. To our knowledge,
8
9 so far, 40 mutations have been described in 52 patients (Supp. Table S1) (Najah, et al., 2009;
10
11 Zamel, et al., 2008). Here, we report 2 children with a severe form of ABL that are compound
12
13 heterozygotes for *MTTP*. The new mutations induce deletion of exon 6 and 10 and translation
14
15 of truncated proteins.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1 New splicing mutations of *MTTP*

2
3 **MATERIALS AND METHODS**

4
5 **Patients:**

6 We report 2 new cases of ABL, whose diagnosis was performed when AM was a 13 month-
7 old boy and his sister PM was 6 years-old. They were born from Caucasian non-
8 consanguineous parents. We received the agreement of both parents for genetic
9 investigations.
10

11
12
13
14
15
16
17 **Endoscopy and duodenal biopsies:**

18 Upper gastrointestinal endoscopy was realized under general anesthesia with a Pentax EG-
19 1870K. Duodenal biopsies were fixed in Bouin for pathology or immediately frozen in liquid
20 nitrogen for further investigations (Western blot and MTTP activity assay). For routine
21 microscopy, biopsies were embedded in paraformaldehyde and sections were
22 hematoxylin/eosin-stained.
23
24
25
26
27
28
29
30

31
32 **Intestinal MTTP analyses:**

33 Proteins were extracted from duodenal biopsies to perform a western blot of MTTP. MTTP
34 activity was measured by radiolabelled TG transfer from donor to acceptor vesicles as
35 previously described (Levy, et al., 2002).
36
37
38
39
40

41
42 **Plasma sample analyses:**

43 Blood samples were collected for lipids, lipoproteins, vitamin A and E investigations, and
44 ALT. TG and TC were measured by an enzymatic method (Roche). HDL and VLDL-
45 cholesterol were measured by a dextran/PEG method (Roche). LDL-cholesterol was
46 calculated by Friedwald method. ApoA-I and apoB were determined by immuno-turbidimetry
47 (Roche).
48
49
50
51
52
53

54
55 **Lipid chromatography:**

56 The FPLC system consisted of a Hitachi L7250 auto-sampler, a L7100 pump system and two
57 detectors: L7400 (Hitachi) and UVD170U (Dionex). 20 μ L of plasma were injected and
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

New splicing mutations of *MTTP*

6

lipoproteins were separated on SuperoseTM6 10/300GL column (GE Healthcare) with 0.15M NaCl solution at a flow rate of 0.4mL/min. The column effluent was split equally into two lines by a microsplitter 50:50, mixing with cholesterol or triglyceride reagents (Biolabo), thus achieving a simultaneous profile from single injection. The two enzymatic reagents were each pumped at a rate of 0.2mL/min. Both enzymatic reactions proceeded at 37°C in a Teflon reactor coil (15mLx0.4mm id). Proteins were measured directly at 280nm.

Genomic DNA sequencing of *MTTP*:

DNA from patients was extracted from blood samples and then exons and introns of *MTTP* gene (NCBI Reference Sequence: NG_011469.1) were sequenced with Applied ABI Prism.

mRNA sequencing of *MTTP*:

Total RNA was extracted using RNeasy Mini Kit (Qiagen) from either EBV-immortalized B lymphocytes for both children or primary lymphocytes for both children and their parents. Primary lymphocytes were isolated from blood samples using a ficoll technique. A reverse transcription was performed and nested PCR was used to amplify exon 6 and exon 10 with 5' and 3' flanking regions (see primers in Supp. Table S2). PCR products were separated on agarose gel, then extracted with a QIAquick Gel Extraction Kit (Qiagen) and directly inserted into pCR2.1 vector (Invitrogen) before sequencing analyses.

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Constructs:

WT-MTTP cDNA was a generous gift of Dr M.Hussain (New-York). We produced by PCR *WT-MTTP* and *MTTP* mutants with deletions of patients: $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP*. PCR fragments (*WT-MTTP*, $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP*) were digested using BamHI and HindIII restriction enzymes, purified with a QIAquick Gel Extraction Kit (Qiagen) and then inserted

1 New splicing mutations of *MTTP*

2
3 in pEGFP-N1 or in p2xMyc-N1, generated by replacing the EGFP from pEGFP-N1 with a
4
5 2xMyc epitope. pDsRed2-ER vector (Clontech) was used to encode an ER marker.
6
7

8 **Cell culture and transfection:**

9
10 HepG2 (human hepatocellular carcinoma), HeLa (human cervix carcinoma) or Caco-2
11
12 (human epithelial colorectal adenocarcinoma) cells were grown in Dulbecco's modified
13
14 Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 0.1
15
16 mM non essential amino acids (Invitrogen), and 100 µg/ml penicillin/streptomycin
17
18 (Invitrogen) in a humidified atmosphere containing 5% CO₂. HepG2 and HeLa cells were
19
20 transfected using GenJuice (Novagen, Merck) or Fugene (Roche) respectively.
21
22

23 **Immunoprecipitation:**

24
25 The cells were lysed for 30 min in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1%
26
27 Nonidet P-40, 10% glycerol) containing protease and phosphatase inhibitors. Soluble material
28
29 was then incubated overnight at 4°C with 5 µg of monoclonal anti-Myc antibody (clone
30
31 9E10) or polyclonal anti-PDI antibody (DL-11). The antigen-antibody complex was incubated
32
33 with a mix of protein-G and protein-A Sepharose for 1h and then washed in lysis buffer
34
35 containing 0.1% Nonidet P-40. The bound proteins were eluted by boiling the beads in
36
37 Laemmli buffer and analyzed by immunoblotting.
38
39
40
41
42

43 **Immunoblotting:**

44
45 The proteins were separated by SDS-polyacrylamide gel electrophoresis under reducing
46
47 conditions, transferred onto nitrocellulose membrane, and analyzed by immunoblotting
48
49 according to standard protocols using indicated antibodies. Anti-MTTP antibody was a
50
51 generous gift of Drs. J. R. Wetterau and H. Jamil. We used a mouse monoclonal antibody
52
53 against Myc (clone 9E10) from BD Biosciences, a rabbit polyclonal antibody against PDI
54
55 (DL-11) from Sigma and a mouse monoclonal antibody against GFP from Roche. HRP-
56
57 labelled secondary antibodies were from Santa-Cruz or Roche Diagnostics.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

New splicing mutations of *MTTP*

8

Immunofluorescence experiments:

HepG2 and HeLa cells were grown on collagen I coated or glass coverslips respectively. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.05% saponin, saturated with PBS containing 10% fetal bovine serum and incubated with the anti-PDI rabbit polyclonal antibody (Sigma) or the anti-Golgin 97 mouse monoclonal antibody (Molecular Probes) and then with Cy3-labelled secondary antibody (Jackson ImmunoResearch Laboratories). Pictures were captured using a Zeiss LSM 510 META confocal microscope equipped with a 63x Plan-Apochromat objective.

Immunological investigation:

Serum immunoglobulin levels were determined by nephelometry. B lymphocyte phenotype and function were analyzed as previously described (Peron, et al., 2008).

New splicing mutations of *MTTP*

RESULTS

Severe form of abetalipoproteinemia:

When AM was 13-months-old, he presented with a failure to thrive. An intestinal malabsorption was suspected on the basis of abdominal distension, abnormal stools (diarrhea or constipation) and hydro-aeric levels on abdominal X-ray. An upper gastrointestinal endoscopy was performed and revealed a white aspect of duodenal villi characteristic of intestinal fat malabsorption and abnormal lipid storage (Figure 1A), as confirmed by histology (large fat inclusions located within enterocytes, Figure 1B). Blood analyses revealed a severe hypocholesterolemia and hypotriglyceridemia without LDL particles and apoB (Table 1). Since parents have normal lipid values as well as apoB and LDL levels, we ruled out a hypo-betalipoproteinemia which is a dominant inheritance disease. Thus ABL was suspected. They also had an increased level of alanine amino-transferase (ALT) and a hyperechogenic aspect of the liver on ultra-sound scan. Furthermore, both children presented a severe vitamin E deficiency secondary to intestinal fat malabsorption. His sister (PM), 6-years-old at the time of diagnosis, had no rotula reflex (the very early diagnosis of AM prevented the development of peripheral neuropathy). However, both of them have no sign of retinopathy.

Abnormal lipoprotein profiles:

We assessed the blood lipoprotein profiles by FPLC analysis. Both children presented a complete absence of LDL and an almost complete absence VLDL in TC and TG moieties (Figure 1C and 1D). Although HDL-cholesterol levels are only 20% of control, HDL particles remain the only lipid class, with a normal ratio of cholesterol ester to TC (Table 1) reflecting a functional lecithin cholesterol acyl-transferase (LCAT) activity. The HDL pattern differs between patient and control. Patient had 2 peaks of HDL particles. The early peak is specific of the patient while the later one appears at the same time than control, as it is suggested by

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

New splicing mutations of *MTTP*

10

the concordance of protein chromatogram. HDL particles of the early peak seem to be cholesterol-enriched and to have less protein than HDL of the second peak.

Immunoglobulin synthesis abnormalities:

Both of these children had also a congenital hypogammaglobulinemia requiring regular immunoglobulin substitution. They were diagnosed as immunodeficient on serum IgG, IgM and IgA levels that were performed because of a failure to thrive in the first months of age (Table 2). There was no protein losing enteropathy. Mild hypogammaglobulinemia was discovered, affecting IgM and IgG in both children. IgA was also slightly decreased in the brother AM during the first years of age. AM and PM had normal T and B cell populations (data not shown). B cell phenotype was found normal in PM but absence of memory switched B cells was observed in the younger brother AM. In contrast, *in vitro* B cell immunoglobulin production was found normal (data not shown).

***MTTP* mutations:**

Genomic DNA sequencing of *MTTP* gene showed 2 different mutations: c.619G>T and c.1237-28A>G (Supp. Table S3). The first one c.619G>T was located at the first nucleotide of exon 6 and the second one c.1237-28A>G was located within intron 9. In order to understand the consequences of such mutations, we extracted mRNA from lymphocytes and analyzed *MTTP* transcripts. *MTTP* is mainly expressed in the liver and in the intestine, but can also be detected from EBV-immortalized B lymphocytes. After reverse transcription and PCR amplification, products were analyzed by gel migration, thereby revealing a decrease in size for both mutations in patient compared to the control (Figure 2A and 2C). As expected, we obtained in control a band at 228 pb and 888 pb for exons 6 and 10 respectively, whereas lower fragments were revealed in patient. Those fragments were detected at the size of ~90pb and ~780pb, suggesting the loss of exons 6 and 10 respectively. Sequencing confirmed that these two mutations are responsible for abnormal splicing of exons 6 and 10

1 New splicing mutations of *MTTP*

11

2
3 respectively (Figure 2B and 2D). The first genomic DNA mutation c.619G>T induces a frank
4
5 deletion of exon 6 and a shift in the open reading frame leading to a premature stop codon at
6
7 position 234 and resulting in an abnormal truncated protein consisting of 233 amino acids
8
9 (~25kDa). The second DNA mutation c.1237-28A>G induces a frank deletion of exon 10 (36
10
11 amino acids), with no shift in the reading frame, leading to a protein of 858 amino acids
12
13 (~94kDa) (Figure 2E).
14
15

16
17
18 These mutations were also confirmed with sequencing analyses from primary
19
20 lymphocytes from parents and children, meaning that abnormal splicing of *MTTP* was a
21
22 consequence of genomic mutations and not of EBV immortalization.
23
24

25 As children are compound heterozygotes, these results confirm the genetic diagnosis
26
27 of ABL.
28

29 **Loss of function of MTTP protein:**

30
31
32 Duodenal biopsies were performed and samples were analyzed for MTTP expression
33
34 and activity. In patient, we detected a band with a slight decrease of the apparent MTTP size
35
36 compared to control or Caco-2 cells (Figure 3A), which probably corresponds to Δ 10-MTTP
37
38 with the loss of 36 amino acids (3kDa) due to exon 10 deletion. We observed no band at a
39
40 size of 25kDa, corresponding to the expected size of Δ 6-MTTP (data not shown), suggesting
41
42 that Δ 6-MTTP might be degraded by the proteasome. MTTP activity was also measured on
43
44 these samples and showed a complete loss of TG transfer activity (5-8%/mg protein in control
45
46 *versus* 0.08-0.8%/mg protein in AM, Figure 3B).
47
48
49

50
51 We further investigated the ability of both Δ 6-MTTP and Δ 10-MTTP mutants to
52
53 interact with PDI and their subcellular localization by first generating constructs encoding
54
55 GFP- or 2xMyc-tagged WT-MTTP, Δ 6-MTTP or Δ 10-MTTP. Tagged MTTP mutants as well
56
57 as WT-MTTP were expressed in HeLa cells and analyzed by immunoblotting. We observed
58
59 that Δ 6-MTTP and Δ 10-MTTP were detected, as well as WT form (Figure 4A and 4B). This
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

New splicing mutations of *MTTP*

12

is in contrast to the mutant MTTP analysis in duodenal biopsy since $\Delta 6$ -MTTP could not be detected. The overexpression level of tagged proteins might overcome the degradation machinery, thereby allowing the detection of a part of $\Delta 6$ -MTTP and $\Delta 10$ -MTTP. However, $\Delta 10$ -MTTP seemed to be lower expressed compared to WT-MTTP, either expressed as GFP- or 2xMyc- $\Delta 10$ -MTTP (quantification in Figure 4C), probably because a part of abnormal proteins was degraded by proteasome.

Since MTTP is localized in the ER through its binding with PDI, we tested the association of MTTP mutants with PDI. 2xMyc-tagged MTTP mutant and WT proteins were expressed in both HeLa and HepG2 cells and immunoprecipitation was performed using anti-myc antibody (Figure 4D) or anti-PDI antibody (Figure 4E). As expected, we found that WT-MTTP interacted with PDI (Figure 4D and 4E, upper panel). By contrast, neither $\Delta 6$ -MTTP nor $\Delta 10$ -MTTP was able to associate with PDI (Figure 4D and 4E, middle and lower panels).

We then investigated the cellular localization of WT-MTTP as well as $\Delta 6$ -MTTP and $\Delta 10$ -MTTP. After expression in both HeLa and HepG2 cells, WT-MTTP, $\Delta 6$ -MTTP and $\Delta 10$ -MTTP displayed an identical pattern, showing a reticular localization throughout the cytosol, reminiscent of ER staining (Supp. Figure S1). However, in HepG2 cells but not in HeLa cells, $\Delta 6$ -MTTP also displays a non specific localization both in the nucleus and throughout the cytosol (Supp. Figure S1B, see inset in $\Delta 6$ -MTTP-GFP), much like GFP alone. This suggests that in HepG2 cells, $\Delta 6$ -MTTP-GFP protein can be degraded, as we observed by immunoblotting in duodenal biopsies. Surprisingly, WT-MTTP as well as $\Delta 6$ -MTTP and $\Delta 10$ -MTTP co-localized with ER markers such as ER-DsRed, a red marker consisting of a fusion of the DsRed and the ER retention sequence, KDEL (Figure 5A) and PDI (Figure 5B). By contrast, no co-localization was observed with cis-Golgi marker such as Golgin 97 (Supp. Figure S2) or trans-Golgi marker such as TGN46 (data not shown).

New splicing mutations of *MTTP*

13

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Altogether, these data showed that MTTP mutants lost TG transfer activity. They are still localized in the ER despite their inability to interact with PDI.

For Peer Review

DISCUSSION

MTTP is mainly expressed in enterocytes and hepatocytes where it participates in the synthesis of chylomicrons and VLDL respectively. These patients presented fat storage in the small intestine (Figure 1A and 1B) and in the liver (as suggested by increased ALT levels and hyperechogenic aspect), as a consequence of MTTP dysfunction.

Lipids are almost exclusively transported in blood into HDL lipoproteins in ABL patients (Figures 1C and 1D and Table 1). These particles are mainly synthesized in peripheral tissues to ensure the reverse cholesterol transport to the liver. But, HDL are also produced at the basolateral membrane of enterocytes, via ATP Binding Cassette-A1 (ABCA1) efflux of cholesterol to apoA-I (Levy, et al., 2007). Cholesterol is transported by enterocytes in two different pathways: the apoB-dependent and the apoB-independent pathways resulting respectively in the production of CM or HDL lipoproteins (Iqbal, et al., 2003). Some differences exist between these two pathways. Cholesterol ester is only secreted within CM while free cholesterol is secreted by both pathways. The apoB-dependent pathway is also regulated by MTTP and contributes to cholesterol absorption during post-prandial states. MTTP is not required for cholesterol secretion by the apoB-independent pathway that may be more important during fasting states. In the human epithelial Caco-2 cell line, Liver X Receptor/Retinoid X Receptor activation increases *ABCA1* gene expression and basolateral efflux of cholesterol in intestinal HDL (Murthy, et al., 2002). In ABL patients, neurological impairment (ataxia and peripheral neuropathy) and retinopathy are the consequences of vitamin E deficiency. Like cholesterol, these two routes also exist for vitamin E absorption by enterocytes (Anwar, et al., 2007). In *MTTP*-deficient enterocytes, the HDL pathway is used to deliver vitamin E. Vitamin E secretion within HDL lipoproteins is not increased by MTTP inhibition (Anwar, et al., 2007). This pathway is not as important as chylomicron synthesis but, in ABL patients, intestinal HDL represent the only route for lipids or vitamin E from

New splicing mutations of *MTTP*

15

1
2
3 intestine to the liver (Anwar, et al., 2007; Anwar, et al., 2006). These ABL patients have a
4
5 specific class of HDL particles that have a lower density and a lower protein content.
6
7

8 MTTP is also expressed in natural killer T (NKT) cells. Inhibition of MTTP in fetal
9
10 thymocyte organ culture results in a complete loss of NKT cells (Dougan, et al., 2007). In
11
12 these antigen presenting cells, MTTP loads lipids onto nascent CD1d and regulates
13
14 presentation of glycolipid antigens (Dougan, et al., 2005). MTTP deficiency could impair the
15
16 recycling of CD1d from lysosome to the plasma membrane (Sagiv, et al., 2007). Interestingly,
17
18 both patients present with a hypogammaglobulinemia that was mild but however required
19
20 immunoglobulin substitution. We only found an absence of memory switched B cells in one
21
22 patient while both of them had a normal *in vitro* immunoglobulin production (Table 2). Since
23
24 such an association between mild B lymphocyte immunodeficiency and abetalipoproteinemia
25
26 has not been previously reported in ABL patients, it is unlikely that MTTP defect is directly
27
28 involved in hypogammaglobulinemia. However, this point should be further investigated,
29
30 looking for a subtle defect in immunoglobulin levels in abetalipoproteinemia patients.
31
32 Recently, Zeissig *et al.* characterized the loss of CD1 function in ABL patients (Zeissig, et al.,
33
34 2010). They found a defect of all antigen-presenting CD1 family members in dendritic cells
35
36 from ABL patients. Similarly to apoB, MTTP deficiency in the ER leads to the degradation of
37
38 group 1 CD1 by the proteasome pathway, which altered activation of NKT cells.
39
40
41
42
43
44

45 In these new patients with ABL, we characterized mutations of *MTTP* by analyzing
46
47 genomic DNA and mRNA products. Sequencing revealed abnormal splicing leading to
48
49 deletion of exon 6 or 10, as a result of two genomic mutations, c.619G>T and c.1237-28A>G
50
51 respectively. c.619G>T is not only a missense mutation (207 Val>Phe), but induces as well an
52
53 abnormal splicing (Mitchell, et al., 1986). The deletion of 140 bp of exon 6 causes a shift in
54
55 the reading frame and a truncated protein because of a premature stop codon in position 234.
56
57
58 Recently, Najah *et al.* (Najah, et al., 2009) found similar results with c.619-3T>G mutation
59
60

New splicing mutations of *MTTP*

16

1
2
3 located in intron 5 of *MTTP*. We showed that this truncated protein is not detected in
4
5 duodenal biopsies (data not shown), suggesting that $\Delta 6$ -*MTTP* is degraded by the proteasome
6
7 pathway (Pan, et al., 2007). c.1237-28A>G located in intron 9 leads to the frank deletion of
8
9 108 bp of exon 10, with no shift in the reading frame, resulting in the loss of 36 amino acids.
10
11

12
13 Human *MTTP* structure contains an N-terminal β -barrel (β^N) (residues 22-297), a
14
15 central α -helical domain (α) (residues 298-603), and two C-terminal β -sheets (β^C and β^A)
16
17 (residues 604-894). β^N is conserved in apoB, lipovitellin, and apolipoprotein and may be one
18
19 of the two phospholipid binding sites of *MTTP*. Helices 4-6, β^C and β^A domains of *MTTP* are
20
21 conserved in vertebrates, but not in invertebrates, suggesting that they are involved in TG
22
23 transfer activity (Rava and Hussain, 2007). β^N mediates the interaction with the N-terminus of
24
25 apoB; the middle α -helical domain mediates the interaction with both PDI (residues 520-598)
26
27 and apoB (residues 517-603); and the C-terminal mediates the lipid-binding and transfer
28
29 catalytic activity of *MTTP* (Mann, et al., 1999; Read, et al., 2000). Expression of *MTTP*
30
31 constructs in HepG2 and HeLa cells showed that $\Delta 6$ -*MTTP* and $\Delta 10$ -*MTTP* proteins are
32
33 located at ER (Figure 5) but are not associated with PDI (Figure 4D and 4E). *MTTP* mutants
34
35 might be retained in the ER as defective or misfolded proteins and a part might be
36
37 retrotranslocated to the cytosol for proteasomal degradation. The truncated $\Delta 6$ -*MTTP* protein
38
39 only conserved one apoB-binding domain. By contrast, $\Delta 10$ -*MTTP* protein is characterized
40
41 by the loss of residues 413-448, that are not directly involved in PDI binding but their loss
42
43 could alter the tertiary structure of the protein. Finally, these residues, corresponding to
44
45 helices 7-9 of the central α -helical domain, belong to a critical domain for TG transfer activity
46
47 as described by Rava and Hussain (Rava and Hussain, 2007).
48
49
50
51
52
53
54
55

56 In conclusion, we report here two new mutations of *MTTP*, c.619G>T and c.1237-
57
58 28A>G, resulting respectively in $\Delta 6$ -*MTTP* protein, a truncated protein of 233 amino acids
59
60 and $\Delta 10$ -*MTTP* protein, deleted of exon 10. Despite these mutations do not change ER

1 New splicing mutations of *MTTP*

17

2
3 localization of mutant *MTTP* proteins, they abolish their binding with PDI and totally
4
5 impaired their TG transfer activity.
6
7

8 9 10 **ACKNOWLEDGEMENTS**

11
12 The authors thank these children and their parents, and also pediatricians taking care of them
13
14 (Dr. E. Fournié-Gardini and Dr. A.I. Bertozzi). We also thank J. Bertrand-Michel and V.
15
16 Roques (Lipidomic Plateau of IFR-BMT/IFR150) for lipidomic analysis, advice and technical
17
18 assistance. We are grateful to Pr. T. Levade (Toulouse, France) for immortalization of B
19
20 lymphocytes.
21
22

23
24 This work was supported by grants from INSERM, ANR (PNRA-2006 ABSINTE) and by
25
26 grants from Canadian Institutes of Health Research, MOP 10584 (E.L). V.P and E.M were the
27
28 recipients of a fellowship from the Fondation pour la Recherche Médicale. V.P is a young
29
30 researcher with temporary contract from INSERM. X.C was a recipient of a “Contrat
31
32 d’Interface” from CHU of Toulouse.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURES LEGENDS**Figure 1. Diagnosis of abetalipoproteinemia**

(A) Upper gastrointestinal endoscopy performed in patient AM revealed a white aspect of duodenal villi, characteristic of lipid storage. (B) Biopsy was performed in duodenum and processed for hematoxylin/eosin-staining. The arrow points at the presence of lipid droplets within the enterocytes. (C and D) Serum from control or patient (AM) was analyzed using FPLC system. Lipoproteins were separated and total cholesterol (C) and triglycerides (D) were measured. Profiles are shown for control (Ctrl) and patient (AM). Proteins were only showed for patient in C. Note the difference of y-axis (lipid content) between control and patient.

Figure 2. Sequence analysis of mutant *MTTP* transcription products

(A and C) After mRNA extraction and reverse transcription from control and patient (AM) EBV-immortalized lymphocytes, PCR was performed to amplify exon 6 (A) and exon 10 (C) with 5' and 3' flanking regions. PCR products were analyzed by migration on agarose gel. Arrowhead points at the lower band found in patient compared to the control. (B and D) Upper bands in the control and lower bands in patients were purified and then cloned into pCR2.1 vector before sequencing. In (B), electrophoregrams showed the exon 6 and 5' and 3' flanking regions with exon 5 and 7 in the control. In the patient, the exon 6 is deleted, leading to a frameshift and a premature stop codon. In (D), similarly, electrophoregrams showed the exon 10 and 5' and 3' flanking regions with exon 9 and 11 in the control. In the patient, the exon 10 is deleted. (E) The amino acid sequences corresponding to exons 6 and 10 are shown underlined and in blue in the normal *MTTP* sequence. // determined the deletion of exons 6 or

New splicing mutations of *MTTP*

19

1
2
3 10 in each mutant. For $\Delta 6$ -MTTP, the frame-shift mutation results in an abnormal sequence
4 described in red and in italic.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

New splicing mutations of *MTTP*

20

Figure 3. MTTP expression and activity in duodenal biopsy

(A) Duodenal biopsy from control (Ctrl) or patient (AM) and Caco-2 cell lysate were analyzed by SDS gel electrophoresis and western blotting with antibodies against MTTP. (B) The triglyceride transfer activity of MTTP was measured on duodenal biopsy from control or patient (AM). Values are expressed as the mean of three independent experiments; standard errors are indicated.

Figure 4. Interaction of WT and mutant MTTP with PDI

(A and B) HeLa cells were transfected or not with WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP tagged with EGFP (A) or 2xMyc (B). Cell lysates (100 μ g) were analyzed by SDS gel electrophoresis and western blotting with antibodies against GFP (A), Myc (B) and Rab5 as loading control. Arrowheads point at WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and arrows point at non specific band (ns). Blots in (B) were scanned and the quantification is shown in (C). Each experiment was repeated at least 3 times, and (C) shows a representative example. (D and E) HeLa cells were transfected with 2xMyc-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP. Cell lysates (Lys) were subjected to immunoprecipitation with (+) or without (-) the anti-myc antibody (D) or the anti-PDI antibody (E). Analysis was performed by SDS gel electrophoresis and western blotting with antibodies against Myc or PDI. Arrowheads point at immunoprecipitated WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP (D) or PDI (E) and arrows point at non specific band (ns). IgG HC represents heavy chain of anti-PDI antibody used for immunoprecipitation.

Figure 5. Localization of WT and mutant MTTP and ER marker

(A) HeLa cells were co-transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and a vector encoding DsRed-ER marker. Cells were then processed for fluorescence

New splicing mutations of *MTTP*

21

analysis. (B) HeLa cells were transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and were then processed for immunofluorescence using anti-PDI antibody. Bar: 10 μ m.

For Peer Review

REFERENCES

- 1
2
3
4
5
6 Al-Shali K, Wang J, Rosen F, Hegele RA. 2003. Ileal adenocarcinoma in a mild phenotype of
7 abetalipoproteinemia. *Clin Genet* 63(2):135-8.
- 8
9 Anwar K, Iqbal J, Hussain MM. 2007. Mechanisms involved in vitamin E transport by
10 primary enterocytes and in vivo absorption. *J Lipid Res* 48(9):2028-38.
- 11
12 Anwar K, Kayden HJ, Hussain MM. 2006. Transport of vitamin E by differentiated Caco-2
13 cells. *J Lipid Res* 47(6):1261-73.
- 14
15
16 Au WS, Lu L, Yeung CM, Liu CC, Wong OG, Lai L, Kung HF, Lin MC. 2008. Hepatocyte
17 nuclear factor 1 binding element within the promoter of microsomal triglyceride
18 transfer protein (MTTP) gene is crucial for MTTP basal expression and insulin
19 responsiveness. *J Mol Endocrinol* 41(4):229-38.
- 20
21
22 Benayoun L, Granot E, Rizel L, Allon-Shalev S, Behar DM, Ben-Yosef T. 2007.
23 Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi
24 Jewish population and a contiguous gene deletion in an Arab patient. *Mol Genet*
25 *Metab* 90(4):453-7.
- 26
27
28
29
30
31 Benoist F, Grand-Perret T. 1997. Co-translational degradation of apolipoprotein B100 by the
32 proteasome is prevented by microsomal triglyceride transfer protein. Synchronized
33 translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride
34 transfer protein. *J Biol Chem* 272(33):20435-42.
- 35
36
37
38 Berthier MT, Couture P, Houde A, Paradis AM, Sammak A, Verner A, Depres JP, Gagne C,
39 Gaudet D, Vohl MC. 2004. The c.419-420insA in the MTP gene is associated with
40 abetalipoproteinemia among French-Canadians. *Mol Genet Metab* 81(2):140-3.
- 41
42
43 Chardon L, Sassolas A, Dingeon B, Michel-Calemard L, Bovier-Lapierre M, Moulin P,
44 Lachaux A. 2008. Identification of two novel mutations and long-term follow-up in
45 abetalipoproteinemia: a report of four cases. *Eur J Pediatr*.
- 46
47
48
49 Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki
50 K, Siegelman ES, Gregg RE and others. 2007. Inhibition of microsomal triglyceride
51 transfer protein in familial hypercholesterolemia. *N Engl J Med* 356(2):148-56.
- 52
53
54 Di Leo E, Lancellotti S, Penacchioni JY, Cefalu AB, Averna M, Pisciotta L, Bertolini S,
55 Calandra S, Gabelli C, Tarugi P. 2005. Mutations in MTP gene in abeta- and
56 hypobeta-lipoproteinemia. *Atherosclerosis* 180(2):311-8.
- 57
58
59
60 Dische MR, Porro RS. 1970. The cardiac lesions in Bassen-Kornzweig syndrome. Report of a
case, with autopsy findings. *Am J Med* 49(4):568-71.

New splicing mutations of *MTTP*

23

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Dougan SK, Rava P, Hussain MM, Blumberg RS. 2007. MTP regulated by an alternate promoter is essential for NKT cell development. *J Exp Med* 204(3):533-45.
- Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, Khurana A, Kronenberg M, Johnson C, Exley M and others. 2005. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. *J Exp Med* 202(4):529-39.
- Heath KE, Luong LA, Leonard JV, Chester A, Shoulders CC, Scott J, Middleton-Price HR, Humphries SE, Talmud PJ. 1997. The use of a highly informative CA repeat polymorphism within the abetalipoproteinaemia locus (4q22-24). *Prenat Diagn* 17(12):1181-6.
- Iqbal J, Anwar K, Hussain MM. 2003. Multiple, independently regulated pathways of cholesterol transport across the intestinal epithelial cells. *J Biol Chem* 278(34):31610-20.
- Iqbal J, Dai K, Seimon T, Jungreis R, Oyadomari M, Kuriakose G, Ron D, Tabas I, Hussain MM. 2008. IRE1beta inhibits chylomicron production by selectively degrading MTP mRNA. *Cell Metab* 7(5):445-55.
- Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. 2008. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. *J Clin Invest* 118(6):2347-64.
- Levy E, Spahis S, Sinnott D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. 2007. Intestinal cholesterol transport proteins: an update and beyond. *Curr Opin Lipidol* 18(3):310-8.
- Levy E, Stan S, Delvin E, Menard D, Shoulders C, Garofalo C, Slight I, Seidman E, Mayer G, Bendayan M. 2002. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. *J Biol Chem* 277(19):16470-7.
- Mitchell PJ, Urlaub G, Chasin L. 1986. Spontaneous splicing mutations at the dihydrofolate reductase locus in Chinese hamster ovary cells. *Mol Cell Biol* 6(6):1926-35.
- Murthy S, Born E, Mathur SN, Field FJ. 2002. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. *J Lipid Res* 43(7):1054-64.
- Najah M, Di Leo E, Awatef J, Magnolo L, Imene J, Pinotti E, Bahri M, Barsaoui S, Brini I, Fekih M and others. 2009. Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia. *Clin Chim Acta* 401(1-2):51-6.
- Narcisi TM, Shoulders CC, Chester SA, Read J, Brett DJ, Harrison GB, Grantham TT, Fox MF, Povey S, de Bruin TW and others. 1995. Mutations of the microsomal

- 1
2
3 triglyceride-transfer-protein gene in abetalipoproteinemia. *Am J Hum Genet*
4 57(6):1298-310.
- 5
6
7 Ohashi K, Ishibashi S, Osuga J, Tozawa R, Harada K, Yahagi N, Shionoiri F, Iizuka Y,
8 Tamura Y, Nagai R and others. 2000. Novel mutations in the microsomal triglyceride
9 transfer protein gene causing abetalipoproteinemia. *J Lipid Res* 41(8):1199-204.
- 10
11
12 Pan X, Hussain FN, Iqbal J, Feuerman MH, Hussain MM. 2007. Inhibiting proteasomal
13 degradation of microsomal triglyceride transfer protein prevents CCl₄-induced
14 steatosis. *J Biol Chem* 282(23):17078-89.
- 15
16
17 Peron S, Metin A, Gardes P, Alyanakian MA, Sheridan E, Kratz CP, Fischer A, Durandy A.
18 2008. Human PMS2 deficiency is associated with impaired immunoglobulin class
19 switch recombination. *J Exp Med* 205(11):2465-72.
- 20
21
22 Raabe M, Flynn LM, Zlot CH, Wong JS, Veniant MM, Hamilton RL, Young SG. 1998.
23 Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in
24 heterozygotes and embryonic lethality in homozygotes. *Proc Natl Acad Sci U S A*
25 95(15):8686-91.
- 26
27
28 Rava P, Hussain MM. 2007. Acquisition of triacylglycerol transfer activity by microsomal
29 triglyceride transfer protein during evolution. *Biochemistry* 46(43):12263-74.
- 30
31
32 Rehberg EF, Samson-Bouma ME, Kienzle B, Blinderman L, Jamil H, Wetterau JR,
33 Aggerbeck LP, Gordon DA. 1996. A novel abetalipoproteinemia genotype.
34 Identification of a missense mutation in the 97-kDa subunit of the microsomal
35 triglyceride transfer protein that prevents complex formation with protein disulfide
36 isomerase. *J Biol Chem* 271(47):29945-52.
- 37
38
39 Ricci B, Sharp D, O'Rourke E, Kienzle B, Blinderman L, Gordon D, Smith-Monroy C,
40 Robinson G, Gregg RE, Rader DJ and others. 1995. A 30-amino acid truncation of the
41 microsomal triglyceride transfer protein large subunit disrupts its interaction with
42 protein disulfide-isomerase and causes abetalipoproteinemia. *J Biol Chem*
43 270(24):14281-5.
- 44
45
46 Sagiv Y, Bai L, Wei DG, Agami R, Savage PB, Teyton L, Bendelac A. 2007. A distal effect
47 of microsomal triglyceride transfer protein deficiency on the lysosomal recycling of
48 CD1d. *J Exp Med* 204(4):921-8.
- 49
50
51 Sakamoto O, Ohura T, Matsubara Y, Takayanagi M, Tsuchiya S. 2007. Mutation and
52 haplotype analyses of the MUT gene in Japanese patients with methylmalonic
53 acidemia. *J Hum Genet* 52(1):48-55.
- 54
55
56
57
58
59
60

New splicing mutations of *MTTP*

25

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Schgoer W, Eller P, Mueller T, Tancevski I, Wehinger A, Ulmer H, Sandhofer A, Ritsch A, Haltmayer M, Patsch JR. 2008. The MTP -493TT genotype is associated with peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) Study. *Clin Biochem* 41(9):712-6.
- Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ and others. 1993. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. *Nature* 365(6441):65-9.
- Sheena V, Hertz R, Nousbeck J, Berman I, Magenheimer J, Bar-Tana J. 2005. Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4alpha. *J Lipid Res* 46(2):328-41.
- Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, Leoni PR, Bhattacharya S, Pease RJ, Cullen PM and others. 1993. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. *Hum Mol Genet* 2(12):2109-16.
- Vongsuvan R, Hooper AJ, Coakley JC, Macdessi JS, O'Loughlin EV, Burnett JR, Gaskin KJ. 2007. Novel mutations in abetalipoproteinaemia and homozygous familial hypobetalipoproteinaemia. *J Inherit Metab Dis* 30(6):990.
- Wang J, Hegele RA. 2000. Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. *Hum Mutat* 15(3):294-5.
- Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. *Science* 258(5084):999-1001.
- Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, Luo J, Kennedy S, Davidson NO. 2006. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific *Mttp* deficiency. *J Biol Chem* 281(7):4075-86.
- Yang XP, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H. 1999. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. *Arterioscler Thromb Vasc Biol* 19(8):1950-5.
- Zamel R, Khan R, Pollex RL, Hegele RA. 2008. Abetalipoproteinemia: two case reports and literature review. *Orphanet J Rare Dis* 3:19.
- Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, Ruggiero G, Adinolfi LE. 2008. Microsomal triglyceride transfer protein (MTP) -

New splicing mutations of *MTTP*

26

1
2
3 493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3
4 infected patients. *J Viral Hepat* 15(10):740-6.
5

6
7 Zhou M, Fisher EA, Ginsberg HN. 1998. Regulated Co-translational ubiquitination of
8 apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory
9 protein. *J Biol Chem* 273(38):24649-53.
10

11
12 Zeissig S, Dougan SK, Barral DC, Junker Y, Chen Z, Kaser A, Ho M, Mandel H, McIntyre A,
13 Kennedy SM and others. 2010. Primary deficiency of microsomal triglyceride transfer
14 protein in human abetalipoproteinemia is associated with loss of CD1 function. *J Clin*
15 *Invest* 120(8):2889-99.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

TABLES

Table 1. Clinical and biological findings in abetalipoproteinemia patients and their parents

	AM	PM	Children Normal Range	Father	Mother	Adults Normal Range
Age (year)	1.3	5.9		40	37	
Weight (kg)	8.2	19		NA	NA	
Height (cm)	75	111		NA	NA	
Triglycerides	6	1	< 75 mg/dL	77	87	50-150 mg/dL
Free cholesterol	7,9	6,6	NA	ND	ND	
Esterified cholesterol	22,1	23,4	NA	ND	ND	
Total cholesterol	30	30	< 170 mg/dL	166	235	105-240 mg/dL
HDL-cholesterol	29	30	> 40 mg/dL	46	69	40-80 mg/dL
VLDL-cholesterol	10	0	ND	16	17	10-30 mg/dL
LDL-cholesterol	0	0	< 110 mg/dL	105	148	108-162 mg/dL
ApoA-I	0.43	0.48	NA	1.25	1.71	1.1-2.1 g/L
Apo-B	0.02	0.01	< 90 mg/dL	0.68	0.92	0.5-1.35 g/L
Retinol/RBP	0.68	1.06	0.95-1.06	ND	ND	
Tocopherol	0.41	0.16	6-15 mg/L	ND	ND	
ALT	60	60	< 36 IU/L	ND	ND	
AST	76	76	< 50 IU/L	ND	ND	

NA: not available; ND: not done.


Table 2. Immunoglobulin levels

	AM, born the 21/01/2004			PM, born the 25/07/1999			
	29/04/2004	11/10/2005	27/07/2010	30/09/1999	29/11/2005	27/07/2010	Normal range
IgG	0.95	7.86	6.48	0.33	8.63	5.47	5.6 - 10.4 g/L
IgA	0.04	0.11	1.11	0.02	1.73	1.67	0.4 - 1.4 g/L
IgM	0.11	0.67	0.73	0.04	0.44	0.36	0.6 - 1.6 g/L


Immunoglobulin levels of both patients were reported at the diagnosis of hypogammaglobulinemia, just after the diagnosis of abetalipoproteinemia and at the last follow-up.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1



C – Total Cholesterol




D - Triglycerides




190x254mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1



C – Total Cholesterol




D - Triglycerides



190x254mm (96 x 96 DPI)

Figure 2




WT-MTP protein:
 MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKTYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGDDDDQLQITMKDYNV
 ENVNDQRGEKSIFKGSFKSKIMGKENLEALQRPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVY
 QAHQDKVVKIKALDSCKIARSGFTTPNQVLYGSSKATSYTTIKIEDSFVAVLAETHINFGLNFLQTIKGGKIVSKOKLELKTTEAGPRLM
 SGKAAAIKAVDSKYTAIPVGVQVFSHCKGCPSSLSELWRSTRKYLQPDNLSKAEAVRNFLAFQHLRTAKKEELQILKMNKEVLPQ
 LYDAVTSAGTSDSLEAILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALIISGRKGSIGSSLEIEYVNIITGTLVWQVCGNEGCKRKA
 VWEAKKILGGLEKAEKKEDTRMYLLALQNALPEGIPSLLYAEAGEGPISHLATTALQRYDLPFTTDEVKKTLLNRVYHONRKYHEKTV
 RTAAAAILNNINPYSYMDVKNILLSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLEKEMVAHNYDRFSRSGSSSAYTYEERSPFSAS
 TYSLDILYSGGILRRSNLNFQYIGKAGLHGSQAVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
 ASGDPISSVVKGLLIDHSQELQLQSGLKANIEVQGLAIDSGAMEFSLWYRESKTRVKNRVTVITTDITVDSSVFKAGLETSTETEAG
 LEFSTVQFSQYFLVCMQMDKDEAPFRQFEKKYERLSTGRGYVSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF

Δ6-MTP protein:
 MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKTYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGDDDDQLQITMKDYNV
 ENVNDQRGEKSIFKGSFKSKIMGKENLEALQRPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVY
 QAHQDKVVKIKALDSCKIARSGFTTPNQVLYGSSKATSYTTIKIEDSFVAVLAETHINFGLNFLQTIKGGKIVSKOKLELKTTEAGPRLM
 SGKAAAIKAVDSKYTAIPVGVQVFSHCKGCPSSLSELWRSTRKYLQPDNLSKAEAVRNFLAFQHLRTAKKEELQILKMNKEVLPQ
 LYDAVTSAGTSDSLEAILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALIISGRKGSIGSSLEIEYVNIITGTLVWQVCGNEGCKRKA
 VWEAKKILGGLEKAEKKEDTRMYLLALQNALPEGIPSLLYAEAGEGPISHLATTALQRYDLPFTTDEVKKTLLNRVYHONRKYHEKTV
 RTAAAAILNNINPYSYMDVKNILLSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLEKEMVAHNYDRFSRSGSSSAYTYEERSPFSAS
 TYSLDILYSGGILRRSNLNFQYIGKAGLHGSQAVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
 ASGDPISSVVKGLLIDHSQELQLQSGLKANIEVQGLAIDSGAMEFSLWYRESKTRVKNRVTVITTDITVDSSVFKAGLETSTETEAG
 LEFSTVQFSQYFLVCMQMDKDEAPFRQFEKKYERLSTGRGYVSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF

Δ10-MTP protein:
 MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKTYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGDDDDQLQITMKDYNV
 ENVNDQRGEKSIFKGSFKSKIMGKENLEALQRPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVY
 QAHQDKVVKIKALDSCKIARSGFTTPNQVLYGSSKATSYTTIKIEDSFVAVLAETHINFGLNFLQTIKGGKIVSKOKLELKTTEAGPRLM
 SGKAAAIKAVDSKYTAIPVGVQVFSHCKGCPSSLSELWRSTRKYLQPDNLSKAEAVRNFLAFQHLRTAKKEELQILKMNKEVLPQ
 LYDAVTSAGTSDSLEAILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALIISGRKGSIGSSLEIEYVNIITGTLVWQVCGNEGCKRKA
 VWEAKKILGGLEKAEKKEDTRMYLLALQNALPEGIPSLLYAEAGEGPISHLATTALQRYDLPFTTDEVKKTLLNRVYHONRKYHEKTV
 RTAAAAILNNINPYSYMDVKNILLSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLEKEMVAHNYDRFSRSGSSSAYTYEERSPFSAS
 TYSLDILYSGGILRRSNLNFQYIGKAGLHGSQAVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
 ASGDPISSVVKGLLIDHSQELQLQSGLKANIEVQGLAIDSGAMEFSLWYRESKTRVKNRVTVITTDITVDSSVFKAGLETSTETEAG
 LEFSTVQFSQYFLVCMQMDKDEAPFRQFEKKYERLSTGRGYVSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF

190x254mm (96 x 96 DPI)

Figure 2



WT-MTTP protein:
MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKLYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGGDDQLQITMKDYNV
ENVNQQRGEKSIFKGSKPSKIMGKENLEALQRPTLLHLHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVITY
QAHQDKVKKALDSCKIARSGFITPNQMLGVSSKATSWTLYKIEDSFVAVLAETINFGLNFLQTKGKIVSKOKLELKTTEAGPRLMS
SGKAAAIKAVDSKYTAIPVQVQVFSHCCKGCPSELSELWRSTRKYLQPDNLKSAEAVRNFLAFQHLRTAKKEELQILKMKENKEVLPQ
LVDAVTSAQTSDSLAEILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALI ~~SRKIKGSSGSSSNINISLWNIITGTLWIKKICDRIKCKIKLKA~~
VWEAKKILGGLKAEKKEDTRMYLLAKNALLPEGIPSLIKYAEAGEGPIHLATLQRVYDLPFTDEVKKTINRIYHQRKVKHEKTV
RTAAAILNNINPASYMDVKNILSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLKEMVAHINVDRFSRSGSSSAYTYIERSPRSAS
TYSLDILYSGSGILRRSNILNIFQYIGKAGLHGSOVVEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
ASGDPISVYKGLLIDHSQELQLQSGLKANIEVQGLAIDISGAMEFSLWYRESKTRVKNRVTVMTTDTVDSSVFKAGLETSTETEAG
LEFSTVQFSQYPLVCMQMDKDEAPFRDFEKYERLSTGRGYYSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF


A6-MTTP protein:
MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKLYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGGDDQLQITMKDYNV
ENVNQQRGEKSIFKGSKPSKIMGKENLEALQRPTLLHLHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVITY
QAHQDKVKKALDSCKIARSGFITPNQ ~~MLGVSSKATSWTLYKIEDSFVAVLAETINFGLNFLQTKGKIVSKOKLELKTTEAGPRLMS~~
SGKAAAIKAVDSKYTAIPVQVQVFSHCCKGCPSELSELWRSTRKYLQPDNLKSAEAVRNFLAFQHLRTAKKEELQILKMKENKEVLPQ
LVDAVTSAQTSDSLAEILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALI ~~SRKIKGSSGSSSNINISLWNIITGTLWIKKICDRIKCKIKLKA~~
VWEAKKILGGLKAEKKEDTRMYLLAKNALLPEGIPSLIKYAEAGEGPIHLATLQRVYDLPFTDEVKKTINRIYHQRKVKHEKTV
RTAAAILNNINPASYMDVKNILSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLKEMVAHINVDRFSRSGSSSAYTYIERSPRSAS
TYSLDILYSGSGILRRSNILNIFQYIGKAGLHGSOVVEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
ASGDPISVYKGLLIDHSQELQLQSGLKANIEVQGLAIDISGAMEFSLWYRESKTRVKNRVTVMTTDTVDSSVFKAGLETSTETEAG
LEFSTVQFSQYPLVCMQMDKDEAPFRDFEKYERLSTGRGYYSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF

A10-MTTP protein:
MILLAVLFLCFSSYSASVKGHTTGLSLNNDRLYLKLYSTEVLLDRGKGLQDSVGYRSSNVDYVALLWRNPDGGDDQLQITMKDYNV
ENVNQQRGEKSIFKGSKPSKIMGKENLEALQRPTLLHLHGKVKEFYSYQNEAVAIENIKRGLASLFTQLSSGTTNEVDISGNCKVITY
QAHQDKVKKALDSCKIARSGFITPNQMLGVSSKATSWTLYKIEDSFVAVLAETINFGLNFLQTKGKIVSKOKLELKTTEAGPRLMS
SGKAAAIKAVDSKYTAIPVQVQVFSHCCKGCPSELSELWRSTRKYLQPDNLKSAEAVRNFLAFQHLRTAKKEELQILKMKENKEVLPQ
LVDAVTSAQTSDSLAEILDFLDFKSDSSILQERFLYACGFASHIPNEELLRALI ~~SRKIKGSSGSSSNINISLWNIITGTLWIKKICDRIKCKIKLKA~~
VWEAKKILGGLKAEKKEDTRMYLLAKNALLPEGIPSLIKYAEAGEGPIHLATLQRVYDLPFTDEVKKTINRIYHQRKVKHEKTV
RTAAAILNNINPASYMDVKNILSIGELPOEMNKYMLAVQDILRFEMPASKVRRVLKEMVAHINVDRFSRSGSSSAYTYIERSPRSAS
TYSLDILYSGSGILRRSNILNIFQYIGKAGLHGSOVVEAQGLEALIAATPDEGEENLDSYAGMSAILFDVOLRPVITFNGYSDLMSKMLS
ASGDPISVYKGLLIDHSQELQLQSGLKANIEVQGLAIDISGAMEFSLWYRESKTRVKNRVTVMTTDTVDSSVFKAGLETSTETEAG
LEFSTVQFSQYPLVCMQMDKDEAPFRDFEKYERLSTGRGYYSQKRKESVLAGCEFFLHQENSEMCKVVFAPQPDSTSSGWF

190x254mm (96 x 96 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3



190x254mm (96 x 96 DPI)


Figure 4



190x254mm (96 x 96 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 5



254x190mm (96 x 96 DPI)

Review

Figure 5

254x190mm (96 x 96 DPI)

Supplementary Table S1. Description of *MTP* mutations reported in the literature

exon/intron mutations	exon/intron mutations	consequency	number of patients	references
intron 9, c.1237-1G>A, maternal unidisomy	intron 9, c.1237-1G>A, maternal unidisomy	abnormal splicing site, exon 10 deletion	1	Yang, et al., 1999
exon 13, c.1820delG	exon 13, c.1820delG	abnormal reading frame	1	Wang, et al., 1999
exon 16, c.2237G>A	exon 18, c.2524A>T	p.G746E / p.K842X	1	Wang, et al., 1999
exon 12, c.1619G>A	exon 12, c.1619G>A	p.R540H	1	Wang, et al., 1999
exon 18, c.2593G>T	exon 18, c.2593G>T	p.G865X	7	Benayoun, et al., 2007 Ricci, et al., 1995 Wang, et al., 1999
exon 10, c.1342A>T	intron 12, 1769+1G>A	p.K448X / abnormal splicing site	1	Wang, et al., 1999
exon 12, c.1769G>T	exon 12, c.1769G>T	p.S590I	2	Al Shali, et al., 2003 Wang, et al., 1999
exon 11, c.1389delA	exon 11, c.1389delA	abnormal reading frame	1	Ohashi, et al., 2000
exon 4, c.419insA	exon 4, c.419insA	abnormal reading frame	3	Al Shali, et al., 2003 Berthier, et al., 2004 Narcisi, et al., 1995 Ohashi, et al., 2000
exon 13, c.1783C>T	intron 15, c.2218-2A>G	p.R595X, abnormal splicing site	1	Ohashi, et al., 2000
exon 16, c.2338A>T	exon 16, c.2338A>T	p.D780Y	1	Ohashi, et al., 2000
exon 9, c.1228delCCCinsT	exon 9, c.1228delCCCinsT	abnormal reading frame	1	Di Leo, et al., 2005
intron 9, c.1237-1G>A	NA	abnormal splicing site, exon 10 deletion	1	Di Leo, et al., 2005
exon 9, c.1151 A>C	exon14, c.1982 G>C	p.D384A / p.G661A	1	Di Leo, et al., 2005
exon 15, c.2212delT	exon 15, c.2212delT	abnormal reading frame	3	Benayoun, et al., 2007 Narcisi, et al., 1995
intron 1, c.148-2A>G	intron 1, c.148-2A>G	abnormal splicing site	2	Benayoun, et al., 2007
exon 3, c.307A>T	exon 3, c.307A>T	p.K103X	1	Benayoun, et al., 2007
large deletion of 481 kb	large deletion of 481 kb	loss of MTP and 8 other genes	1	Benayoun, et al., 2007
exon 15, c.2076-39_2303+52del319	exon 15, c.2076-39_2303+52del319	exon 15 deletion	1	Vongsuvan, et al., 2007
exon 2, c.215delC	exon 2, c.215delC	abnormal reading frame	1	Sharp, et al., 1993
exon 13, c.1783C>T	exon 13, c.1783C>T	p.R595X	2	Chardon, et al., 2009 Sharp, et al., 1993
exon 17, c.2346insACTG	exon 17, c.2346insACTG	abnormal reading frame	1	Heath, et al., 1997
exon1, c.59del17	exon1, c.59del17	abnormal reading frame	1	Chardon, et al., 2009
exon 5, c.582C>A	exon 5, c.582C>A	p.Cys194X	2	Chardon, et al., 2009
intron 5, c.619-3T>G	intron 5, c.619-3T>G	abnormal splicing site, exon 6 deletion	1	Najah, et al., 2009
exon 8, c.923G>A	exon 8, c.923G>A	p.W308X	1	Najah, et al., 2009
exon 10, c.1237-1344del107	exon 12, c.1619G>A	exon 10 deletion / p.R540H	1	Rehberg JBC 1996
exon 9, c.1147delA	exon 9, c.1147delA	abnormal reading frame	1	Narcisi, et al., 1995
intron 10, c.1344+5del7	intron 10, c.1344+5del7	abnormal splicing site	1	Narcisi, et al., 1995
exon 4, c.419insA	exon 11, 1401insA	abnormal reading frame	1	Narcisi, et al., 1995

intron 13, c.1867+1G>A	intron 14, c.1990-1G>A	abnormal splicing site / abnormal splicing site	1	Narcisi, et al., 1995
exon 4, c.419insA	intron 13, c.1867+5G>A	abnormal reading frame / abnormal splicing site	1	Narcisi, et al., 1995
intron 13, c.1867+5G>A	intron 13, c.1867+5G>A	abnormal splicing site	2	Narcisi, et al., 1995 Shoulders, et al., 1993
intron 1, 147+2T>C	exon 4, c.419insA	abnormal splicing site / abnormal reading frame	1	Dische, et al., 1970
intron 1, 147+1G>C	exon 12, c.1692T>C	abnormal splicing site / p.I564T	1	Sakamoto, et al., 2006
exon 6, c.619G>T	intron 9, c.1237-28A>G	abnormal splicing site / abnormal splicing site	2	this report

Supplementary Table S2. PCR primers

	sens	antisens	amplicon (bp)
exon 10	5' GGAGAGGTTTCTCTATGCCT 3'	5' GCCAGTTGCTGACAGCATT 3'	997
nested exon 10	5' ATCCCAATGAAGAACTCCTGAGA 3'	5' CAAAGAGGATGGCTGACATACC 3'	888
exon 6	5' GACCTACCAGGCTCATCAAGACA 3'	5' GATGTCTGAAAGCAGGCTGC 3'	294
nested exon 6	5' GGCCTTGGATTTCATGCAAAATAGCG 3'	5' GCCTGCTTCGGTTGTCTTCAGC 3'	228

Supplementary Table S3. Genomic mutations of *MTTP*

<i>MTTP</i> locus	Allele 1	Allele 2
AM	c.619G>T	c.1237-28A>G
PM	c.619G>T	c.1237-28A>G
Father	c.619G>T	normal
Mother	normal	c.1237-28A>G
Translation product	exon 6 deletion	exon 10 deletion

Supplementary Figure S1: Localization of WT and mutant MTTP

HeLa cells (A) or HepG2 cells (B) were transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and were then processed for immunofluorescence. Bar: 10 μ m.


Supplementary Figure S2: Localization of WT and mutant MTTP and Golgi marker

HeLa cells were transfected with GFP-tagged WT-MTTP, $\Delta 6$ -MTTP or $\Delta 10$ -MTTP and were then processed for immunofluorescence using anti-Golgin 97 antibody. Bar: 10 μ m


For Peer Review

Supplementary Figure S1

A




B



190x254mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure S2



190x254mm (96 x 96 DPI)